+23648073gothi_gothi@gothi.gov.egالأحد إلى الخميس — 8:00 ص إلى 3:00 م--:--:--
العاصمة الإدارية الجديدة — الحي الحكومي
الهيئة العامة للمستشفيات والمعاهد التعليميةالهيئة العامة للمستشفيات والمعاهد التعليميةGOTHI — Teaching Hospitals & Institutesنساعد في تطوير المستقبل الطبى لمصر
تواصل معنا
الرئيسية
عن الهيئة

عن الهيئة

عرض الكل

قائمة عن الهيئة

7 عنصرًا
  • من نحن
  • كلمة رئيس الهيئة
  • الرؤية و الرساله والقيم
  • مجلس الإدارة
  • الهيكل الإدارى
  • بروتوكولات التعاون
  • القواعد واللوائح
التثقيف و التوعيه الصحية
المستشفيات والمعاهد
معاهد ومدارس التمريض
المركز الاعلامى

المركز الاعلامى

عرض الكل

قائمة المركز الاعلامى

5 عنصرًا
  • أخبار الهيئة
  • إنجازات طبية
  • الفاعليات و المؤتمرات
  • زيارات
  • المكتبة الإعلامية
الخدمات
خدمات بحثية4
  • منصة الأبحاث
  • المجلة العلمية
  • المكتبة الالكترونية
  • لجنة أخلاقيات البحث العلمي
خدمات تدريبيه3
  • مركز تدريب رئاسة الهيئة
  • البورد العربي
  • ايفاد التدريب
خدمــات طبيه متمـيزة6
  • المبادرات الرئاسية
  • مركز دعم الباحثين
  • جائزة النشر الدولية
  • نبذه عن دعم الباحثين
  • خدمات مركز دعم الباحثين
  • اتصل بنا
عرض جميع الخدمات
Gothi Profile
الرئيسيةعن الهيئةالتثقيف و التوعيه الصحيةالمستشفيات والمعاهدمعاهد ومدارس التمريضالمركز الاعلامىالخدماتGothi Profile
GOTHI

الهيئة العامة للمستشفيات والمعاهد التعليمية

GOTHI — Teaching Hospitals & Institutes

نساعد في تطوير المستقبل الطبى لمصر

إقرأ من الموقع

  • اتفاقيات و بروتوكلات تعاون
  • دعم الباحثين
  • التثقيف والتوعية الصحية
  • المركز الإعلامي
  • الدلائل الارشادية
  • بروتوكولات الطوارئ

روابط هامة

  • وزارة الصحة والسكان
  • بنك المعرفة المصري
  • ١٠٠ مليون صحة
  • منظومة الشكاوى الحكومية الموحدة
  • مركز تدريب هيئة المستشفيات التعليمية

تواصل معنا

  • مواعيد العمل: من الأحد إلي الخميس — 8:00 ص حتى 3:00 م
  • العاصمة الإدارية الجديدة — الحي الحكومي
  • +23648073
  • gothi_gothi@gothi.gov.eg
جميع الحقوق محفوظة © 2026 — الهيئة العامة للمستشفيات والمعاهد التعليميةSINCE 1975
  1. الرئيسية
  2. الدلائل الإرشادية
  3. طب بشرى
  4. طب نساء وتوليد

طب نساء وتوليد

Clinical Guideline · 01

Non-Clinical Interventions to reduce overall cesarean sections

last update: 8 February 2024”
– Executive summary13 بندعرض التوصيات
“last update: 8 February 2024”  
 

– Executive summary

 

➡️Introduction

The number of women who deliver by Cesarean section has increased steadily in Egypt over the last three decades, from 4.6% in 1992 (1) to 51.8% in 2014 (2).

Cesarean birth is associated with short- and long-term risks that can extend many years beyond the current delivery and affect the health of the woman, the child, and future pregnancies. High rates of cesarean section are associated with substantial health-care costs (3).

The factors contributing to the rise in cesarean section rates are complex, and identifying interventions to address them is challenging. Factors associated with cesarean births include changes in the characteristics of the population such as increase in the prevalence of multiple pregnancies, assisted reproduction, and increase in the proportion of nulliparous women with advanced age. Other non-clinical factors such as women increasingly wanting to determine how and when their child is born, generational shifts in work and family responsibilities, physician factors, increasing fear of medical litigation, as well as organizational, economic and social factors have all been implicated in this increase (4).

The sustained, unprecedented rise in cesarean section rates in Egypt is a major public health concern. There is an urgent need for evidence-based guidance to address the trend. This is the national guideline on non-clinical interventions (defined as interventions applied independently of a clinical encounter between a health-care provider and a patient in the context of patient care).

The objective of this guideline is to provide evidence-based recommendations on non-clinical interventions specifically designed to reduce cesarean sections. Clinical interventions that could help to reduce cesarean section rates are being prepared in a second guideline.

➡️Target audience

The primary audience for this guideline includes health-care professionals including obstetricians, midwives, nurses, and general medical practitioners, as well as managers of maternal and child health programs and public health policymakers in Egypt.

➡️Guideline development methods

We used the GRADE-Adolopment methodology for the guideline adaptation process (5). Briefly, this included, identifying and training guideline panelists, prioritizing questions and outcomes, identifying existing guideline (6), assessing quality and adaptability of the identified guideline, reviewing GRADE evidence tables and EtD frameworks, and formulating and grading strength of recommendations.

The identified existing guideline was developed by the WHO in accordance with standard procedures set out in the WHO handbook for guideline development (7). The evidence, in the identified guideline, on the effectiveness of interventions was derived from an updated Cochrane review of 29 studies (8). 


 

  Jump to activity

Clinical Guideline · 02

Rationalizing the use of caesarean section in Egypt through implementing 10 group Classification system

last update: 12 June 2025
Download Guideline
– Objectives9 بندعرض التوصيات
“last update: 12 June 2025                                                                                        Download Guideline
 

– Objectives

 

·       Be aware of the cs rate and its burden on health system .

·       Help you to recognize the absolute indications of cs .

·       Help you in assessing and validating the relative indications of CS.

·       Helps you to understand and implement the Robson Classification and build the Report Table using your own data

·       Identify the complications of CS

·       To help healthcare facilities and obstetricians in adopting and using the Robson Classification. It presents a standard approach to implement and interpret this classification

·       Explains the variables and definitions used and how to produce and interpret the Report Table

·       Highlights challenges that you may encounter and shares useful experiences and examples from users

Clinical Guideline · 03

The diagnosis and management of ectopic pregnancy & pregnancy of unknown location

last update: 2 July 2025”
Download Guideline
– Executive Summary220 بندعرض التوصيات
“last update: 2 July  2025”                                                                                                         Download Guideline
 

– Executive Summary

 

This guideline offers evidence-based recommendations on the management of ectopic pregnancy and pregnancy of unknown location. The recommendations are intended to provide healthcare professionals with practical guidance on appropriate and timely diagnosis and choosing the best evidence-based treatment modality of ectopic pregnancy resulting in improving health outcomes for people with this potentially fatal condition.

List of Recommendations:

 

 

Recommendation

Strength

Counselling and documentation

 

Women should be given information at the time of diagnosis of an ectopic pregnancy regarding their diagnosis and management. They should be counselled regarding signs of clinical deterioration when they should present for review and given information about emergency contacts

Strong

Diagnosis of tubal ectopic pregnancy

 

A urinary beta-human chorionic gonadotrophin (β-hCG) test should be performed in all women of reproductive age presenting to a maternity or adult general hospital/unit with abdominal pain, vaginal bleeding, gastrointestinal symptoms, dizziness, or collapse

Strong

A thorough gynaecological, obstetric, medical, and surgical history should be taken to assess for risk factors for ectopic pregnancy in women who present with the above symptoms; however, half of women with an ectopic pregnancy will have no known risk factors

Strong

A physical examination, including measurement of vital signs, should be performed to assess haemodynamic stability in women presenting with the above symptoms

Strong

There should be prompt escalation of care if there are any red flag symptoms on triage assessment or abnormal vital signs in the presence of a positive urinary HCG

Strong

All the above women are recommended to undergo ultrasound scanning

GPS

Consider a transabdominal ultrasound scan for women with an enlarged uterus or other pelvic pathology, such as fibroids or an ovarian cyst

Conditional

Offer women who attend an early pregnancy a transvaginal ultrasound scan to identify the location of the pregnancy and whether there is a fetal pole and heartbeat. If a transvaginal ultrasound scan is unavailable or unacceptable to the woman, offer a transabdominal ultrasound scan and explain the limitations of this method of scanning

Strong

When carrying out a transvaginal ultrasound scan in early pregnancy, look for these signs indicating there is a tubal ectopic pregnancy: An adnexal mass, moving separate to the ovary, comprising a gestational sac containing a yolk sac and/or fetal pole (with or without fetal heartbeat)

GPS

When carrying out a transvaginal ultrasound scan in early pregnancy, look for these signs indicating a high probability of a tubal ectopic pregnancy: An adnexal mass, moving separately to the ovary, with an empty gestational sac (“tubal ring” or “bagel sign”) or a complex, inhomogeneous adnexal mass, moving separate to the ovary. If these features are present, take into account other intrauterine and adnexal features on the scan, the woman’s clinical presentation, and serum HCG levels before making a diagnosis

GPS

When carrying out a transvaginal ultrasound scan in early pregnancy, look for these signs indicating a possible ectopic pregnancy: An empty uterus or collection of fluid within the uterine cavity (pseudo-sac). If these features are present, take into account other intrauterine and adnexal features on the scan, the woman’s clinical presentation, and serum HCG levels before making a diagnosis

GPS

When carrying out a transabdominal or transvaginal ultrasound scan in early pregnancy, look for a moderate to large amount of free fluid in the peritoneal cavity or pouch of Douglas, which might represent hemoperitoneum. If this is present, take into account other intrauterine and adnexal features of the scan, the woman’s clinical presentation, and HCG levels before making a diagnosis

GPS

When carrying out a transabdominal or transvaginal ultrasound scan during early pregnancy, scan the uterus and adnexa to see if there is a heterotopic pregnancy

GPS

All ultrasound scans should be performed or directly supervised and reviewed by appropriately qualified healthcare professionals with training in, and experience of, diagnosing ectopic pregnancies

GPS

Be aware that women with a pregnancy of unknown location could have an ectopic pregnancy until the location is determined

Conditional

Do not use serum HCG measurements to determine the location of the pregnancy

Strong

In a woman with a pregnancy of unknown location, place more importance on clinical symptoms than on serum HCG results, and review the woman’s condition if any of her symptoms change, regardless of previous results and assessments

Strong

Use serum HCG measurements only for assessing trophoblastic proliferation to help to determine subsequent management

Strong

Take 2 serum HCG measurements as near as possible to 48 hours apart (but no earlier) to determine subsequent management of a pregnancy of unknown location. Take further measurements only after review by a senior healthcare professional

Strong

Regardless of serum HCG levels, women with a pregnancy of unknown location should be counseled about what to do if they experience any new or worsening symptoms, including details about how to access emergency care 24 hours a day. Advise women to return if there are new symptoms or if existing symptoms worsen

Strong

For a woman with an increase in serum HCG levels greater than 63% after 48 hours:

–    Inform her that she is likely to have a developing intrauterine pregnancy (although the possibility of an ectopic pregnancy cannot be excluded).

–    Offer her a transvaginal ultrasound scan to determine the location of the pregnancy between 7 and 14 days later. Consider an earlier scan for women with a serum HCG level greater than or equal to 1,500 IU/liter.

–    If a viable intrauterine pregnancy is confirmed, offer her routine antenatal care.

–    If a viable intrauterine pregnancy is not confirmed, refer her for immediate clinical review by a senior gynaecologist

Strong

For a woman with a decrease in serum HCG levels greater than 50% after 48 hours: inform her that the pregnancy is unlikely to continue but that this is not confirmed and provide her with information about where she can access support and counselling services. Ask her to take a urine pregnancy test 14 days after the second serum HCG test, and explain that:

–    if the test is negative, no further action is necessary.

–    if the test is positive, she should return to the early pregnancy assessment service for clinical review within 24 hours

Strong

For a woman with a decrease in serum HCG levels less than 50%, or an increase less than 63%, refer her for clinical review in the early pregnancy assessment service within 24 hours

Strong

For women with a pregnancy of unknown location, when using serial serum HCG measurements, do not use serum progesterone measurements as an adjunct to diagnose either viable intrauterine pregnancy or ectopic pregnancy.

Strong

Diagnosis of Pregnancy of unknown location

 

Pregnancy of unknown location is a transient state in the diagnostic process, leading to a final diagnosis of viable or nonviable intrauterine pregnancy, ectopic pregnancy, or persistent pregnancy of unknown location

Strong

   

If pregnancy location cannot be determined on a TVUS, serial serum β-hCG measurements should be used in conjunction with a woman’s history and symptoms to guide management

Strong

Diagnosis of interstitial/cornual pregnancy

 

Interstitial: Many are diagnosed at first trimester scanning by the presence of an eccentric gestational sac. A thin surrounding myometrial layer helps to distinguish this from an angular intrauterine pregnancy. A further sonographic sign is the presence of an echogenic line running from the endometrial cavity to the gestational sac

GPS

Cornual: Presentation may be delayed and is usually with abdominal pain. About 50% present after rupture and morbidity is high. The sensitivity of ultrasound diagnosis is low. The appearance is of a gestation sac separate from an empty unicornuate uterus which is identified by the single interstitial tube. The sac is mobile and surrounded by a thick myometrial layer. A vascular pedicle may be seen joining the gestational sac and the lateral aspect of the empty unicornuate uterus.

GPS

Diagnosis of Cervical pregnancy

 

Implantation is within the cervical canal. Common predisposing factors are curettage, caesarean section or cervical surgical procedures. Usually, the first complaint is of painless vaginal bleeding and speculum examination may reveal an open external cervical os with a fleshy mass protruding

Conditional

Ultrasound shows a gestation sac distal to a closed internal cervical os. Doppler demonstration of surrounding vasculature helps distinguish a cervical pregnancy from a displaced intrauterine pregnancy. In addition, gentle pressure with the transvaginal probe may elicit the “sliding sign” whereby a miscarrying sac is seen to slide within the cervical canal unlike the cervical pregnancy which is fixed

GPS

Diagnosis of ovarian pregnancy

 

Apart from the few cases with a clear-cut yolk sac or fetal pole visible in the ovary, ultrasound diagnosis is difficult. The ring surrounding an EP usually shows greater echogenicity than the surrounding ovarian tissue unlike the ring of a corpus luteum cyst which is less echogenic. If laparoscopy for suspected EP reveals that the tubes are normal a close inspection of the ovaries should be performed. Typically, an ovarian EP has the appearance of a cystic haemorrhagic mass

GPS

Diagnosis of abdominal pregnancy

 

Diagnosis is difficult and is usually made intraoperatively

GPS

Diagnosis of CS scar pregnancy

 

Ultrasound imaging is the primary imaging modality for CSEP diagnosis, although a correct and timely determination can be difficult. The initial finding of a low, anteriorly located gestational sac should raise concern for a possible CSEP and warrants further investigation

Strong

Transvaginal ultrasound imaging is the optimal modality for the evaluation of suspected CSEP because it provides the highest image resolution. Grayscale combined with color Doppler ultrasound imaging is recommended for CSEP diagnosis

Strong

US criteria to diagnose CSEP: (1) an empty uterine cavity and endocervix; (2) placenta, gestational sac, or both embedded in the hysterotomy scar; (3) a triangular (at 8 weeks of gestation) or rounded or oval (at >8 weeks of gestation) gestational sac that fills the scar “niche” (the shallow area representing a healed hysterotomy site); (4) a thin (< 3 mm) or absent myometrial layer between the gestational sac and bladder; (5) a prominent or rich vascular pattern at or in the area of a cesarean scar; and (6) an embryonic or fetal pole, yolk sac, or both, with or without fetal cardiac activity. All of these criteria may not be observed especially with very early diagnosis and before fetal cardiac activity, the patient should have confirmation of pregnancy (for example, a positive pregnancy test result). Bulging or ballooning of the lower uterine segment in the midline sagittal transabdominal view has also been considered to be supportive of CSEP diagnosis

Strong

In cases in which ultrasound imaging is inconclusive, MRI could be considered as an adjunct study. Given the risks associated with delayed diagnosis

Conditional

Hysteroscopy and laparoscopy can be used to confirm a diagnosis at the time of planned operative intervention. With laparoscopic examination, CSEP has been described as an ecchymotic bulge with a “salmon-red” appearance beneath the bladder at the level of the previous cesarean scar with an otherwise normal-appearing uterus

Conditional

Expectant management of tubal ectopic pregnancy

 

Offer expectant management as an option to women who:

–    Are clinically stable and pain-free and

–    Have a tubal ectopic pregnancy measuring <35 mm with no visible heartbeat on transvaginal ultrasound scan and

–    Have serum hCG levels of ≤1000 IU/L and

–    Are able to return for follow-up

Strong

For women with a tubal ectopic pregnancy being managed expectantly, repeat hCG levels on days 2, 4, and 7 after the original test, and:

–    If hCG levels drop by ≥15% from the previous value on days 2, 4, and 7, then repeat weekly until a negative result (<20 IU/L) is obtained

–    If hCG levels do not fall by 15%, stay the same, or rise from the previous value, review the woman’s clinical condition and seek senior advice to help decide further management

Strong

Advise women that, based on limited evidence, there seems to be no difference following expectant or medical management in:

–    The rate of ectopic pregnancies ending naturally

–    The risk of tubal rupture

–    The need for additional treatment, but that they might need to be admitted urgently if their condition deteriorates

–    Health status, depression or anxiety scores. Advise women that the time taken for ectopic pregnancies to resolve and future fertility outcomes are likely to be the same with either expectant or medical management

Strong

Methotrexate treatment for tubal ectopic pregnancy

 

Offer systemic methotrexate to women who have no significant pain and have an unruptured tubal ectopic pregnancy with an adnexal mass smaller than 35 mm with no visible heartbeat and have a serum hCG level less than 1,500 IU/litre and do not have an intrauterine pregnancy (as confirmed on an ultrasound scan) and are able to return for follow-up

Strong

Methotrexate should only be offered on a first visit when there is a definitive diagnosis of an ectopic pregnancy, and a viable intrauterine pregnancy has been excluded. Offer surgery where treatment with methotrexate is not acceptable to the woman. For women with ectopic pregnancy who have had methotrexate, take 2 serum hCG measurements in the first week (days 4 and 7) after treatment and then 1 serum hCG measurement per week until a negative result is obtained. If hCG levels plateau or rise, reassess the woman’s condition for further treatment

Strong

Women receiving methotrexate for the management of tubal ectopic pregnancy can be advised that there is no effect on ovarian reserve

GPS

It is recommended that women treated with methotrexate wait at least 3 months before trying to conceive again

GPS

Surgical treatment for tubal ectopic pregnancy

 

Offer surgery as a first-line treatment to women who are unable to return for follow-up after methotrexate treatment or who have any of the following:

–    an ectopic pregnancy and significant pain

–    an ectopic pregnancy with an adnexal mass of 35 mm or larger

–    an ectopic pregnancy with a fetal heartbeat visible on an ultrasound scan

–    an ectopic pregnancy and a serum hCG level of 5,000 IU/litre or more

Strong

Offer the choice of either methotrexate or surgical management to women with an ectopic pregnancy who have a serum hCG level of at least 1,500 IU/litre and less than 5,000 IU/litre, who are able to return for follow-up and who meet all of the following criteria:

–    no significant pain

–    an unruptured ectopic pregnancy with an adnexal mass smaller than 35 mm with no visible heartbeat

–    no intrauterine pregnancy (as confirmed on an ultrasound scan). Advise women who choose methotrexate that their chance of needing further intervention is increased and they may need to be urgently admitted if their condition deteriorates

Strong

Laparoscopy for tubal ectopic pregnancy

 

When surgical treatment is indicated for women with an ectopic pregnancy, it should be performed laparoscopically whenever possible, taking into account the condition of the woman and the complexity of the surgical procedure.

Strong

Surgeons providing care to women with ectopic pregnancy should be competent to perform laparoscopic surgery.

Strong

Commissioners and managers should ensure that equipment for laparoscopic surgery is available.

Strong

Salpingectomy and salpingotomy

 

Offer a salpingectomy to women undergoing surgery for an ectopic pregnancy unless they have other risk factors for infertility

Strong

Consider salpingotomy as an alternative to salpingectomy for women with risk factors for infertility such as contralateral tube damage

Conditional

Inform women having a salpingotomy that up to 1 in 5 women may need further treatment. This treatment may include methotrexate and/or a salpingectomy.

For women who have had a salpingotomy, take 1 serum hCG measurement at 7 days after surgery, then 1 serum hCG measurement per week until a negative result is obtained

Strong

Advise women who have had a salpingectomy that they should take a urine pregnancy test after 3 weeks. Advise women to return for further assessment if the test is positive

Strong

Management of Cervical ectopic pregnancy

Cervical dilation and curettage may provoke bleeding. Infiltration of the cervix with a haemostatic vasoconstricting agent, followed by the placement of cervical sutures to temporarily occlude the descending branches of the uterine arteries followed by suction curettage (without dilation) and post-curettage cervical canal balloon tamponade has proven successful in treating first trimester cervical pregnancies. Another treatment option is uterine artery embolisation which has been used in combination with MTX 1B

Strong

Management of Interstitial and cornual pregnancy

 

The optimal method of treatment for interstitial ectopic pregnancy has not been determined and needs further research. Cases should be managed on an individual patient basis and a consultant Obstetrician/Gynaecologist should be involved in decision making and management.

GPS

Expectant management of interstitial ectopic pregnancy should be used with caution due to the high mortality associated with rupture of an interstitial ectopic pregnancy but can be considered when β-hCG levels are falling and the pregnancy is non-viable.

Strong

Intramuscular or local methotrexate treatment may be considered in asymptomatic women who fit the criteria for medical management, with follow up serum β-hCG levels.

Strong

Surgical management may be considered for interstitial ectopic pregnancy and is required when there is evidence of rupture, with follow up β-hCG levels.

GPS

Laparoscopic linear cornuostomy is carried out in a similar manner to salpingostomy for EP including allowing spontaneous closure of the corneal incision.

GPS

Cornual resection is another option. Surgical cornual excision is usually preferred either by laparoscopy or open surgery and avoids the risk of recurrence.

GPS

Treatment for a rudimentary horn ectopic pregnancy is excision of the rudimentary horn via laparoscopy or laparotomy.

Strong

Management of ovarian pregnancy

 

Optimum management is resection of the ovarian pregnancy with preservation of healthy ovarian tissue. Follow-up hCG monitoring is recommended. MTX is appropriate for persistent trophoblast and has also been used for primary treatment but is limited in this regard due to the need for laparoscopic and histologic confirmation of diagnosis.

GPS

Management of Heterotopic pregnancy

 

Clinicians should not offer systemic methotrexate in the presence of a desired intrauterine pregnancy.

Conditional

Management of Cesarean scar pregnancy

 

We recommend against expectant management of cesarean scar ectopic pregnancy.

Strong

We suggest that operative resection (with transvaginal or laparoscopic approaches when possible) or ultrasound-guided uterine aspiration be considered for the surgical management of cesarean scar ectopic pregnancy and that sharp curettage alone be avoided.

Conditional

We suggest intra-gestational methotrexate for the medical treatment of cesarean scar ectopic pregnancy, with or without other treatment modalities.

Conditional

We recommend that systemic methotrexate alone not be used to treat cesarean scar ectopic pregnancy.

Strong

In patients who choose expectant management and continuation of a cesarean scar ectopic pregnancy, we recommend repeated cesarean delivery between 34 0/7 and 35 6/7 weeks of gestation.

Strong

We recommend that patients with a cesarean scar ectopic pregnancy be advised of the risks of another pregnancy and counseled regarding effective contraceptive methods, including long-acting reversible contraception and permanent contraception.

Strong

Management of abdominal ectopic pregnancy

 

Clinicians may choose either laparotomy or laparoscopy to excise an abdominal pregnancy

Conditional

Anti-D immunoglobulin prophylaxis

 

Offer anti-D immunoglobulin prophylaxis at a dose of 250 IU (50 micrograms) to all rhesus-negative women who have a surgical procedure to manage an ectopic pregnancy or a miscarriage.

Strong

Do not offer anti-D immunoglobulin prophylaxis to women who:

–   receive solely medical management for an ectopic pregnancy.

–   have a pregnancy of unknown location.

Strong

Do not use a Kleihauer test for quantifying feto-maternal haemorrhage.

Strong

Follow up

 

An early pregnancy ultrasound scan at 6 weeks’ gestation should be performed in any subsequent pregnancy due to the increased risk of ectopic pregnancy recurrence.

Clinical Guideline · 04

Prevention and Treatment of Hypertension in Pregnancy

last update: 2 July 2025”
Download Guideline
– Executive Summary272 بندعرض التوصيات
“last update: 2 July  2025”                                                                                                          Download Guideline
 

– Executive Summary

 

EHC has developed the present evidence-informed recommendations with a view to promoting the best possible clinical practices for the Prevention and Treatment of Hypertension in Pregnancy.

List of Recommendations

Recommendation

Strength

Definitions And Classification

HDPs should be classified according to the criteria and definitions presented in “Glossary”

GPS

Diagnose Hypertension in pregnancy when systolic blood pressure is ≥140mmHg and/or diastolic blood pressure is ≥90mmHg, based on the average of at least 2 measurements, taken at least 15minutes apart, using the same arm.

Strong

Severe hypertension (sBP ≥ 160 and/or dBP ≥ 110 mmHg), can be confirmed within a short interval (minutes) to facilitate timely antihypertensive therapy

Conditional

Gestational hypertension is hypertension that develops for the first time at > 20 weeks, without evidence of preeclampsia

Conditional

Women with gestational hypertension should undergo testing for preeclampsia to rule it out.

Strong

Diagnose preeclampsia in women with new onset hypertension after 20 weeks and new-onset proteinuria or one/more adverse conditions (defined as a maternal end organ complication or evidence of uteroplacental dysfunction)

Strong

Preeclampsia superimposed on chronic hypertension is diagnosed by the development of 1 or more characteristics of preeclampsia (i.e., new-onset proteinuria or 1 or more adverse conditions) superimposed on chronic hypertension

Strong

Do not use an elevation in BP to make a diagnosis of preeclampsia superimposed on chronic hypertension.

Conditional

 

 

Risk factors

Risk factors for developing preeclampsia should be included in the antenatal assessment of all pregnant women.

GPS

Screening

All pregnant women should be screened for their risk of developing preeclampsia early in the pregnancy.

Strong

The screening tool utilized should be determined based on the locally available resources

Conditional

Blood Pressure measurement

During every antenatal visit, screening for preeclampsia in pregnant women with blood pressure measurements throughout pregnancy is strongly recommended

Strong

Testing For Proteinuria

Screen for proteinuria with urinary dipstick at first visit and at each subsequent visit

Conditional

More definitive testing for proteinuria (by urinary protein:creatinine ratio or 24-hour urine collection) is encouraged when there is a suspicion of preeclampsia, including: ≥1+ dipstick proteinuria in women with hypertension and rising blood pressure and in women with normal blood pressure, but symptoms or signs suggestive of preeclampsia       

Conditional

When quantitative methods are not available or rapid decisions are required, a urine protein dipstick reading can be substituted using 2+ as the discriminant value

Conditional

Proteinuria testing does not need to be repeated once significant proteinuria in the setting of confirmed pre-eclampsia has been detected

Conditional

Biomarkers and ultrasonography screening

The use of a combined first trimester screen (combined maternal features, biomarkers and sonography) to identify women at risk of developing preeclampsia is conditionally recommended based on local availability and access to the required resources

Conditional

Risk Reduction

Low dose Aspirin

To reduce the risk of developing preeclampsia, pregnant women with one high risk factor or two or more moderate risk factors for developing preeclampsia should receive low dose aspirin (100 mg -150 mg daily) beginning at 12 weeks gestation and till delivery.

Strong

The use of aspirin at bedtime is conditionally recommended

Conditional

Cessation of aspirin between 34 weeks gestation and birth is conditionally recommended. Exact timing of cessation should be based on individualized clinical judgment and informed, shared decision taking with the women

Conditional

Oral calcium Supplementation

The use of supplemental calcium is strongly recommended in pregnant women with low dietary calcium intake (<1g/day) for the prevention of preeclampsia, preterm birth, and gestational hypertension

Strong

Calcium supplementation at doses of 1.5–2.0 g elemental calcium/day is recommended from the first antenatal visit till delivery, to reduce the risk of developing preeclampsia

Strong

Education

Pregnant women with hypertension or with risk factors for developing preeclampsia should be educated about the symptoms and signs that require immediate attention and referral to health care facilities.

Strong

A clear referral plan should be discussed with each woman

Conditional

Educate pregnant women to seek a healthcare professional immediately if they experience any of the symptoms of pre-eclampsia

Strong

Exercise and diet

Moderate intensity exercise, in the form of aerobic, stretching and/or muscle resistance exercises, for a total of 2.5-5 hours a week, as recommended exercise regimen for general pregnancy wellbeing is encouraged.

Conditional

What is Not recommended for risk reduction

Dietary salt restriction, for prevention of preeclampsia, is not recommended given the lack of evidence of benefit

Conditional

The use of oral omega-3 long-chain polyunsaturated fatty acids LCPUFA supplementation for the prevention of preeclampsia, is not recommended until more data are available

Conditional

The use of oral garlic supplementation, specifically for the prevention of preeclampsia, is not recommended until more data are available

Conditional

The use of oral vitamin C and E supplementation, specifically for the prevention of preeclampsia, is not recommended until more data are available

Conditional

There is inadequate data to recommend for the use or against the use of oral magnesium supplementation specifically for the prevention of preeclampsia. More data on the safety profile is required

Conditional

The use of progesterone replacement, specifically for the prevention of preeclampsia, is not recommended until more data are available

Conditional

The use of statins, specifically for the prevention of preeclampsia, is not recommended until more data are available

Conditional

The use of low molecular weight heparin (LMWH) alone (without aspirin) in women without a history of thrombophilia or APLS can be considered if a contraindication to aspirin is present. The decision to use LMWH (at a prophylactic dose) should be individualized based on women’s clinical and obstetric history and through a shared, informed decision-making process

Conditional

LMWH should not replace the use of aspirin in women without contraindications to aspirin

Conditional

The use of low molecular weight heparin (LMWH) in addition to aspirin for prevention of preeclampsia in women without a history of thrombophilia or APLS is not recommended

Conditional

The use of nitric oxide (either in donor or precursor forms) for the prevention of preeclampsia is not recommended until more data are available

Conditional

The use of metformin, specifically for the prevention of preeclampsia is not recommended until more data are available

Conditional

The use of oral vitamin D supplementation for the prevention of preeclampsia, is not recommended until more data are available

Conditional

The use of proton pump inhibitors for prevention of preeclampsia is not recommended until more data are available

Conditional

The use of clopidogrel for prevention of preeclampsia is not recommended until human data are available

GPS

TREATMENT OF PRE-ECLAMPSIA SYNDROME AND GESTATIONAL HYPERTENSION

Hospital Admission Versus Ambulatory Outpatient Management

Ambulatory outpatient management at home is an option only for women with mild to moderate gestational hypertension and requires frequent fetal and maternal evaluation

Strong

Hospitalization is appropriate for Women with gestational hypertension in whom adherence to frequent monitoring is a concern and for patients diagnosed with preeclampsia

Strong

Ambulatory outpatient management

At each antenatal care visit, following the detection of hypertension in pregnancy, a systematic clinical evaluation of symptoms, signs, laboratory investigations and fetal wellbeing must be performed

Strong

Frequency of appointments is based on the individual clinical needs; suggested review is initially weekly to fortnightly (every 2 weeks) at a minimum

Conditional

Women with non-severe hypertension during pregnancy should not be offered antihypertensive drug treatment when adequate resources for good quality antenatal care follow-up may be lacking

Conditional

Inpatient Care

Women with preeclampsia should have additional tests to detect multisystem involvement, and should have fetal surveillance to assure fetal wellbeing

Strong

A clear referral plan for patients with severe preeclampsia must be developed and implemented in every health care unit

GPS

Complete bed rest is not advised for fear of thromboembolism, however minimal activities with 2 hours afternoon nap and 8 hours night sleep is recommended.

GPS

Non-severe hypertension should be treated with the first-line agents oral methyldopa, labetalol, or nifedipine

Conditional

Severe hypertension in pregnancy (i.e., sBP ≥ 160 mmHg or dbp ≥ 110 mmHg) requires urgent antihypertensive therapy, in a monitored setting

Strong

Severe hypertension should be treated with the first-line agents oral nifedipine, oral labetalol, IV labetalol, or IV hydralazine

Conditional

The target BP for antihypertensive therapy should be a dBP of 85 mmHg, regardless of sBP

Conditional

Use of corticosteroid (either betamethasone or dexamethasone) is recommended in women with preeclampsia who are at risk of birth at < 34 weeks’ gestation

Conditional

There are insufficient data to recommend routine use of corticosteroid in women with preeclampsia who are at risk of birth between 34- and 36-weeks’ gestation. Delivery should not be delayed for the administration of steroids in the late preterm period

Conditional

The use of magnesium sulphate for fetal neuroprotection in women with preeclampsia at risk of preterm birth at < 30 weeks’ gestation is strongly recommended

Strong

As part of expectant management, in-utero transfer to a tertiary-level centre with neonatal intensive care capacity should be considered

GPS

Inpatient Expectant care versus Delivery

Inpatient Expectant care

Women with mild to moderate gestational hypertension or preeclampsia without severe features, expectant management up to 37 0/7 weeks of gestation is recommended

Conditional

In low-resource setting where maternal and neonatal care and adequate resources for close monitoring by healthcare personnel may be lacking or is not available, the GDG recommend against expectant management for preeclampsia with severe hypertension or other severe features

Conditional

Capabilities for the evaluation of fetal wellbeing and detection of fetal compromise should be available in healthcare facilities providing care for pregnant women with hypertensive disorders

Conditional

Transfer of women with hypertension of pregnancy should be considered in situations where the health care provider believes that the health care facility is unequipped to manage the complications of hypertension of pregnancy

GPS

Birth and Delivery

Time of Birth

Initiate birth at ≥ 37 weeks gestation, in women with preeclampsia

Conditional

At < 37 weeks gestation, the decision on expectant management with continued surveillance is appropriate for women with non-severe preeclampsia.

Conditional

At 34+0 till 36+6 weeks gestation for women with preeclampsia in presence of any feature of severity initiation of delivery should is considered. Delivery should not be delayed for the administration of steroids in the late preterm period

Conditional

From fetal viability until <34+0 weeks gestation, Expectant management should be considered, but only in hospitals where very preterm infants and sick mothers can be cared for. Initiation of birth is considered in the absence of available resources for maternal and neonatal care

Conditional

Maternal stabilization and labor management of pre-eclampsia and eclampsia

Prevention and treatment of convulsions

The prevention of eclampsia is empirically based on the timely delivery once preeclampsia has been diagnosed

GPS

Prophylactic magnesium sulphate with an intravenous loading dose of 4g followed by maintenance at 1g/hr for 24 hours in total or time of last seizure is strongly recommended in women at risk of eclampsia or recurrent eclampsia

Conditional

There is inadequate evidence to support an alternative magnesium regimen or the use of anticonvulsants for the prevention of eclampsia

Conditional

It is recommended that magnesium sulfate should be used for the prevention and treatment of seizures in women with severe hypertension or severe preeclampsia, or eclampsia and birth is planned within 24 hours

Conditional

The prophylactic use of magnesium sulfate for the prevention of seizures in women with gestational hypertension or preeclampsia without severe features is Conditionally recommended

GPS

Women with eclampsia should receive magnesium sulphate to prevent recurrent seizures

Conditional

Control of acute severe hypertension

Severe hypertension in pregnancy (i.e., sBP ≥ 160 mmHg or dBP ≥ 110 mmHg) requires urgent antihypertensive therapy, in a monitored setting

Conditional

Severe hypertension should be treated with the first-line agents oral nifedipine, oral labetalol, intravenous (IV) labetalol, or IV hydralazine

Strong

The target BP for antihypertensive therapy should be a dBP of 85 mmHg, regardless of sBP

Conditional

Non-severe hypertension should be treated with the first-line agents oral methyldopa, labetalol, or nifedipine

Conditional

Control of other complications: HELLP syndrome

For women with severe preeclampsia with features of HELLP expectant management is harmful. Plan birth as soon as feasible

Strong

Platelet transfusion should be considered if a woman’s platelet count is <20 _ 109/L before vaginal delivery or <50 _ 109/L before cesarean delivery, or at any time if there is excessive active bleeding, known platelet dysfunction, rapidly falling platelet count, or coagulopathy

Conditional

Vaginal delivery is the preferred modality, unless urgent delivery is necessary for maternal stabilization or for fetal indications. The delivery options should be discussed by a multidisciplinary team and consider the safest mode of delivery to the mother, how fast she is expected to deliver, what are the resources of blood products and other supportive mechanisms available, and can she sustain a surgery

Conditional

In rapidly progressing preeclampsia with severe features or HELLP syndrome, vaginal delivery may be attempted if cervical conditions are favorable and delivery is anticipated within a short timeframe (e.g., ≤2 hours). If labor progress is slow (>6 hours) or maternal/fetal status worsens, immediate cesarean delivery is indicated

Conditional

In small to medium size health care facilities, it is important to estimate whether their blood bank can support a massive blood trans fusion and, if necessary, contact regional or larger hospitals for assistance or for transferring the patient

GPS

Mode of Birth

For women with any HDP, vaginal delivery should be considered unless a cesarean delivery is required for obstetrical indications.

Strong

Vaginal delivery may require early cervical ripening and induction

Conditional

If urgent or emergent delivery is required for maternal and/or fetal indications, an emergency cesarean delivery may be indicated

Strong

Urgency ot Birth

Health facilities in Egypt should provide local protocols of management for their health care providers in accordance with WHO recommendations.

Strong

GDG recommends to nationally adopt a color-triage system for acute obstetric emergencies (Modified Early obstetric warning score -MEOWS)

GPS

TREATMENT OF CHRONIC HYPERTENSION

Expectant Management

Offer expectant management for women with Chronic hypertension who are <37 weeks and, whose blood pressure is lower than 160/110 mmHg with or without antihypertensive treatment, unless there are other medical indications62

Strong

Offer antihypertensive treatment to pregnant women who have chronic hypertension and who are not already on treatment if they have sustained systolic blood pressure of 140 mmHg or higher or sustained diastolic blood pressure of 90 mmHg or higher

Strong

The target BP for antihypertensive therapy should be a dBP of 85 mmHg, regardless of sBP

Strong

Consider labetalol to treat chronic hypertension in pregnant women. Consider nifedipine for women in whom labetalol is not suitable or methyldopa if both labetalol and nifedipine are not suitable. Base the choice on any pre-existing treatment, side-effect profiles, risks (including fetal effects) and the woman’s preference

Conditional

Continue with existing antihypertensive treatment if safe in pregnancy, or switch to an alternative treatment, unless sustained systolic blood pressure is less than 110 mmHg or sustained diastolic blood pressure is less than 70 mmHg or the woman has symptomatic hypotension

Conditional

Offer pregnant women with chronic hypertension aspirin 150 mg once daily from 12 weeks

Strong

Give the same advice on rest, exercise and work to women with chronic hypertension or at risk of hypertensive disorders during pregnancy as healthy pregnant women

Conditional

Offer PLGF testing between 20–36+6 weeks to rule out pre-eclampsia in women with chronic hypertension if clinical suspicion arises

Conditional

In chronic hypertension with suspected pre-eclampsia, monitor proteinuria 1–2x weekly alongside BP checks

Strong

A complete blood count and levels of serum transaminases, lactate dehydrogenase, and uric acid should be checked on diagnosis then weekly

Conditional

Timing of birth

Do not offer planned early birth (before 37 weeks) to women with chronic hypertension whose blood pressure is lower than 160/110 mmHg, with or without antihypertensive treatment, unless there are other medical indications

Strong

Offer planned birth to women with chronic hypertension whose blood pressure is lower than 160/110 mmHg with or without antihypertensive treatment after 37 weeks

Strong

Determination of timing should be agreed between the woman and the obstetrician. Initiation of delivery can be offered at 38+0 to 39+6 weeks

Conditional

Offer planned early birth before 37 weeks to women with chronic hypertension or gestational hypertension if inability to control maternal blood pressure despite using 3 or more classes of antihypertensives in appropriate doses or if any of the known features of severe superimposed preeclampsia develop

Strong

Care for women with hypertension during labor and postpartum

Intrapartum Care

During labour, measure blood pressure hourly. In women with severe hypertension measure blood pressure every 15 to 30 minutes until blood pressure is less than 160/110 mmHg.

Conditional

Continue use of antenatal antihypertensive treatment during labour

Conditional

Do not preload women who have severe pre-eclampsia with intravenous fluids before establishing low-dose epidural analgesia or combined spinal epidural analgesia

Conditional

Do not routinely limit the duration of the second stage of labour in women with controlled hypertension

Conditional

Consider operative or assisted birth in the second stage of labour for women with severe hypertension whose hypertension has not responded to initial treatment

Conditional

As women with preeclampsia are at increased risk of postpartum hemorrhage, the third stage of labour should be actively managed

Conditional

Ergometrine should not be administered to women with any hypertensive disorder of pregnancy, particularly preeclampsia or gestational hypertension; alternative oxytocic drugs should be considered

Strong

Postpartum care for women with HDP

There remains inadequate data to suggest the superiority of a single agent or group of agents in selecting antihypertensives for the management of hypertension in the postpartum period. The choice of antihypertensive (beta-blockers, methyldopa, hydralazine, nifedipine, enalapril, clonidine) should be made through a shared decision-making process, particularly in breastfeeding/lactating women

Conditional

Women should be informed of the long-term risks associated with preeclampsia, gestational hypertension and chronic hypertension and the importance of postpartum follow up prior to discharge from hospital

Conditional

Antihypertensive therapy administered antepartum should be continued after birth. Also, consideration should be given to administering antihypertensive therapy for any hypertension diagnosed before six days postpartum

Conditional

The target dBP for postpartum antihypertensive treatment should be 85 mmHg, as antenatally

Conditional

Non-steroidal anti-inflammatory drugs (NSAIDs) for postpartum analgesia may be used in women with pre-eclampsia if other analgesics are ineffective, and there is no acute kidney injury (AKI) or other risk factors for it

Conditional

Breastfeeding is recommended

Strong

Counselling should be provided about the risks of gestational hypertension (at least 4%) or pre-eclampsia (at least 15%) in future pregnancy

Conditional

At 3 months postpartum, all women should be reviewed to ensure that BP, urinalysis, and any laboratory abnormalities have normalised. If proteinuria or hypertension persist, then appropriate referral for further investigations should be initiated

Conditional

At 6 months postpartum, where possible, all women should be reviewed again, at which point we suggest that BP ≥ 120/80 mmHg lead to discussion of lifestyle change

Conditional

Following hypertensive pregnancy, particularly pre-eclampsia, counselling should be provided about the heightened health risks for the mother (particularly cardiovascular) and the offspring

Strong

 


 

Clinical Guideline · 05

Placenta Accreta Spectrum (PAS): Diagnosis and Management

last update: 14 July 2025”
Download Guideline
– Executive Summary117 بندعرض التوصيات
“last update: 14 July  2025”                                                                                                     Download Guideline
 

– Executive Summary

 

This guideline offers evidence-based recommendations on Placenta Accreta Spectrum. The recommendations are intended to provide healthcare professionals with practical guidance on diagnosis and management of Placenta Accreta Spectrum which can significantly reduce complications and improve the outcome for affected women and their infants.

List of Recommendations

Recommendation

 

Strength

What are the risk factors for women with placenta accreta spectrum?

 

 

The major risk factors for placenta accreta spectrum are history of accreta in a previous pregnancy, previous caesarean delivery and other uterine surgery, including repeated endometrial curettage. This risk rises as the number of prior caesarean sections increases.

Strong Recommendation

Women requesting elective caesarean delivery for non-medical indications should be informed of the risk of placenta accreta spectrum and its consequences for subsequent pregnancies.

GPS

How can placenta accreta spectrum be suspected and diagnosed antenatally?

 

 

Antenatal diagnosis of placenta accreta spectrum is crucial in planning its management and has been shown to reduce maternal morbidity and mortality.

Strong Recommendation

Ultrasound assessment of placental location should be part of routine obstetric care, particularly in women undergoing cesarean section delivery.

GPS

Previous caesarean delivery and the presence of an anterior low-lying placenta or placenta praevia should alert the antenatal care team of the higher risk of placenta accreta spectrum.

Strong Recommendation

Ultrasound screening and diagnosis of placenta accreta spectrum

 

 

Ultrasound imaging is highly accurate when performed by a skilled operator with experience in diagnosing placenta accreta spectrum.

Strong Recommendation

Refer women with any ultrasound features suggestive of placenta accreta spectrum to a specialist unit with imaging expertise.

Strong Recommendation

Standardised definitions should be used in reporting and consideration given to using a template.

GPS

Women with a history of previous caesarean section seen to have an anterior low-lying placenta or placenta praevia at the routine fetal anomaly scan should be specifically screened for placenta accreta spectrum.

Strong Recommendation

Patients with previous one or more CS and diagnosed as CS scar pregnancy at 5-6 weeks of gestation are at high risk of developing placenta accreta. They should be counseled and referred to a tertiary hospital for termination of pregnancy.

Strong Recommendation

Is there a role for magnetic resonance imaging (MRI) in the diagnosis of placenta accreta spectrum?

 

 

Clinicians should be aware that the diagnostic value of MRI and ultrasound imaging in detecting placenta accreta spectrum is similar when performed by experts. 

Strong Recommendation

MRI may be used to complement ultrasound imaging to assess the depth of invasion and lateral extension of myometrial invasion, especially with posterior placentation and/or in women with ultrasound signs suggesting parametrial invasion.

GPS

Women with a history of previous cesarean delivery or uterine surgery who are found to have an anterior low-lying placenta or placenta previa should be considered at increased risk for placenta accreta spectrum, even if imaging does not confirm the diagnosis.

GPS

Where should women with placenta accreta spectrum be cared for?

 

 

Women diagnosed with placenta accreta spectrum should be cared for by a multidisciplinary team in a specialist centre with expertise in diagnosing and managing invasive placentation.

GPS

Prevention and treatment of anemia during the antenatal period is recommended for women with placenta praevia, a low-lying placenta or accreta as for any pregnant woman.

GPS

Delivery for women diagnosed with placenta accreta spectrum should take place in a specialist centre with logistic support for immediate access to blood products, adult intensive care unit and neonatal intensive care unit by a multidisciplinary team with expertise in complex pelvic surgery.

Strong Recommendation

When should delivery be planned for women with placenta accreta spectrum?

 

 

In the absence of risk factors for preterm delivery in women with placenta accreta spectrum, planned delivery at 35+0 to 36+6 weeks of gestation provides the best balance between fetal maturity and the risk of unscheduled delivery.

GPS

Planning delivery of women with suspected placenta accreta spectrum

 

 

Once the diagnosis of placenta accreta spectrum is made, a contingency plan for emergency delivery should be developed in partnership with the woman, including the use of an institutional protocol for the management of maternal hemorrhage.                        

GPS

What should be included in the consent form for caesarean section in women with suspected placenta accreta spectrum?

 

 

Any woman giving consent for caesarean section should understand the risks associated with caesarean section in general, and the specific risks of placenta accreta spectrum in terms of massive obstetric hemorrhage, increased risk of lower urinary tract damage, the need for blood transfusion and the risk of hysterectomy.

Strong recommendation

Additional possible interventions in the case of massive hemorrhage should also be discussed, including cell salvage and interventional radiology where available.

Conditional recommendation

What healthcare professionals should be involved?

 

 

The elective delivery of women with placenta accreta spectrum should be managed by a multidisciplinary team, which should include senior anesthetists, obstetricians and gynecologists with appropriate experience in managing the condition and other surgical specialties if indicated. In an emergency, the most senior clinicians available should be involved.

Strong Recommendation

What anesthetic is most appropriate for delivery?

 

 

The choice of anesthetic technique for caesarean section for women with placenta accreta spectrum should be made by the anesthetist conducting the procedure in consultation with the woman prior to surgery.

GPS

The woman should be informed that the surgical procedure can be performed safely with regional anesthesia but should be advised that it may be necessary to convert to general anesthesia if required and asked to consent to this.

GPS

What surgical approach should be used for women with placenta accreta spectrum?

 

 

Intravenous tranexamic acid should be administered at the commencement of surgery because it reduces intraoperative blood loss.

Strong recommendation

Caesarean section hysterectomy with the placenta left in situ is preferable to attempting to separate it from the uterine wall.

Strong recommendation

When the extent of the placenta accreta is limited in depth and surface area, and the entire placental implantation area is accessible and visualised (i.e., completely anterior, fundal or posterior without deep pelvic invasion), uterus preserving surgery may be appropriate, including partial myometrial resection.

Conditional recommendation

Uterus preserving surgical techniques should only be attempted by surgeons working in teams with appropriate expertise to manage such cases and after appropriate counselling regarding risks and with informed consent.

Conditional recommendation

There are currently insufficient data to recommend the routine use of ureteric stents in placenta accreta spectrum. The use of stents may have a role when the urinary bladder is invaded by placental tissue.

GPS

What surgical approach should be used for women with placenta percreta?

 

 

There is limited evidence to support uterus preserving surgery in placenta percreta and women should be informed of the high risk of peripartum and secondary complications, including the need for secondary hysterectomy.

GPS

When is interventional radiology indicated?

 

 

Larger studies are necessary to determine the safety and efficacy of interventional radiology before this technique can be advised in the routine management of placenta accreta spectrum. 

Strong recommendation

How are women with undiagnosed or unsuspected placenta accreta spectrum best managed at delivery?

 

 

If at the time of an elective repeat caesarean section, where both mother and baby are stable, it is immediately apparent that placenta percreta is present on opening the abdomen, the caesarean section should be delayed until the appropriate staff and resources have been assembled and adequate blood products are available. This may involve closure of the maternal abdomen and urgent transfer to a specialist unit for delivery. 

 

 

GPS

In case of unsuspected placenta accreta spectrum diagnosed after the birth of the baby, the placenta should be left in situ and an emergency hysterectomy performed. 

 

GPS

 

 

Clinical Guideline · 06

The diagnosis and management of endometriosis

last update: 28 July 2025”
Download Guideline
– Executive Summary363 بندعرض التوصيات
“last update: 28 July  2025”                                                                                                     Download Guideline
 
 

– Executive Summary

 

This guideline offers evidence-based recommendations on diagnosis and management of female pelvic endometriosis. The recommendations are intended to provide healthcare professionals with practical guidance on appropriate and timely diagnosis and choosing the best evidence-based treatment modality of female pelvic endometriosis. resulting in improving health outcomes for people with this potentially disabling condition.

List of Recommendations

Recommendation

Strength

Diagnosis of endometriosis

 

Symptoms:

Clinicians should consider the diagnosis of endometriosis in individuals presenting with the following cyclical and non-cyclical signs and symptoms: dysmenorrhea, deep dyspareunia, dysuria, dyschezia, painful rectal bleeding or haematuria, shoulder tip pain, catamenial pneumothorax, cyclical cough/haemoptysis/ chest pain, cyclical scar swelling and pain, fatigue, and infertility

 

 

GPS

Signs:

 Offer an abdominal and pelvic examination to people with suspected endometriosis to identify abdominal masses and pelvic signs, such as reduced organ mobility and enlargement, tender nodularity in the posterior vaginal fornix, and visible vaginal endometriotic lesions.

 

GPS

If rectal endometriosis is suspected, a rectal examination may also be proactively performed to confirm the status of the bowel wall.

 

GPS

Diagnostic imaging

 

Women with suspected endometriosis, further diagnostic steps, including imaging, should be considered even if the clinical examination is normal

Strong

Clinicians are recommended to use imaging (US or MRI) in the diagnostic work-up for endometriosis, but they need to be aware that a negative finding does not exclude endometriosis, particularly superficial peritoneal disease

 

Strong

Offer a transvaginal ultrasound scan to all women with suspected endometriosis, even if pelvic or abdominal examination is normal, to: identify ovarian endometriomas and deep endometriosis

 

Conditional

If a transvaginal scan is declined or not appropriate, consider transabdominal ultrasound scan of the pelvis

 

GPS

Do not use pelvic MRI as the primary investigation to diagnose endometriosis in people with symptoms or signs suggestive of endometriosis.

 

Conditional

Consider pelvic MRI to assess the extent of deep endometriosis involving the bowel, bladder or ureter

 

Conditional

Laparoscopy: surgical diagnosis

 

In patients with negative imaging results, or where empirical treatment (hormonal contraceptives or progestogens) was unsuccessful, consider offering laparoscopy for the diagnosis and treatment of suspected endometriosis

 

GPS

Laparoscopic identification of endometriotic lesions should be confirmed by histopathologic examination of the lesions. However, a negative histology does not entirely rule out the disease

 

GPS

The procedure should be performed by a trained laparoscopic surgeon, who should perform and document a systematic inspection of the pelvis and abdomen

 

GPS

Biomarker:

Do not use serum CA125 to diagnose endometriosis.

 

Strong

Treatment of endometriosis associated pain

 

Pain control in endometriosis

 

For women with pain associated with endometriosis-, consider a short trial (for example, 3 months) of a non-steroidal anti-inflammatory drug (NSAID) alone or in combination with paracetamol, if not contraindicated. If such a trial does not provide adequate pain relief, consider other forms of pain management and referral for secondary or tertiary care center.

 

GPS

Advise patients that there is no evidence for or against the use of anti-neuropathic medications for pain associated with endometriosis

 

GPS

Women with endometriosis should be referred to a pain specialist and/or a condition-specific specialist at any stage if:

• pain is severe and unresponsive to simple analgesics.

• the pain substantially limits daily activities.

• any underlying health condition has deteriorated.

 

Conditional

Hormonal treatment for endometriosis

 

It is recommended to offer women hormone treatment (combined hormonal contraceptives, progestogens, GnRH agonists or GnRH antagonists) as one of the options to reduce endometriosis-associated pain

 

Strong

The GDG recommends that clinicians take a shared decision-making approach and take individual preferences, side effects, individual efficacy, costs, and availability into consideration when choosing hormone treatments for endometriosis-associated pain

 

GPS

When appropriate a levonorgestrel-releasing intrauterine system or an etonogestrel-releasing subdermal implant to reduce endometriosis-associated pain can be used

Strong

It is recommended to prescribe women GnRH agonists to reduce endometriosis-associated pain, although evidence is limited regarding dosage or duration of treatment

Strong

The GDG recommends that GnRH agonists are prescribed as second line (for example if hormonal contraceptives or progestogens have been ineffective) due to their side-effect profile

GPS

Clinicians should consider prescribing combined hormonal add-back therapy alongside GnRH agonist therapy to prevent bone loss and hypoestrogenic symptoms

Strong

In women with endometriosis-associated pain refractory to other medical or surgical treatment, it is recommended to prescribe aromatase inhibitors, as they reduce endometriosis-associated pain. Aromatase inhibitors may be prescribed in combination with oral contraceptives, progestogens, GnRH agonists or GnRH antagonists

Strong

Surgical management for endometriosis

 

Laparoscopic management should be done by an expert in laparoscopic surgery

GPS

When surgery is performed, clinicians may consider excision instead of ablation of endometriosis to reduce endometriosis-associated pain

Conditional

It can be concluded that LUNA is not beneficial as an additional procedure to conventional laparoscopic surgery for endometriosis, PSN is beneficial for treatment of endometriosis-associated midline pain as an adjunct to conventional laparoscopic surgery

GPS

When performing surgery in women with ovarian endometrioma, clinicians should perform cystectomy instead of drainage and coagulation,

 

Strong

When performing surgery for ovarian endometrioma, specific caution should be used to minimize ovarian damage

Strong

Clinicians can consider performing surgical removal of deep endometriosis, as it may reduce endometriosis-associated pain and improves quality of life

Conditional

The GDG recommends that patients undergoing surgery particularly for deep endometriosis are informed on potential risks, benefits, and long-term effect on quality of life

 

GPS

Due to the heterogeneity of patient population, presentation, surgical approaches and techniques, it is difficult to make definitive recommendations on the specific techniques to be applied for the treatment of pain associated with deep endometriosis

 

GPS

In case of bowel endometriosis, a conservative approach should be chosen whenever possible.

GPS

Hysterectomy for endometriosis associated pain

 

Clinicians can consider hysterectomy (with or without removal of the ovaries) with removal of all visible endometriosis lesions, in those women who no longer wish to conceive and failed to respond to more conservative treatments.

Conditional

The GDG recommends that when hysterectomy is performed, a total hysterectomy is preferred

GPS

When a decision is made whether to remove the ovaries, the long-term consequences of early menopause and possible need for hormone replacement therapy should be considered

GPS

Studies should evaluate factors that can be assessed prior to surgery and can predict a clinically meaningful improvement of pain symptoms. Such prognostic markers can be used to select patients that may benefit from endometriosis surgery

GPS

Women may be offered postoperative hormone treatment to improve the immediate outcome of surgery for pain in women with endometriosis if not desiring immediate pregnancy

Conditional

Non-medical interventions in endometriosis

 

No recommendations can be made for any specific non-medical intervention (Chinese medicine, nutrition, electrotherapy, acupuncture, physiotherapy, exercise, and psychological interventions) to reduce pain or improve quality of life measures in women with endometriosis, as the potential benefits and harms are unclear.

GPS

Treatment of endometriosis associated infertility

 

Ovarian suppression

 

In infertile women with endometriosis, clinicians should not prescribe ovarian suppression treatment to improve fertility.

Strong

Women seeking pregnancy should not be prescribed postoperative hormone suppression with the sole purpose to enhance future pregnancy rates.

strong

Those women who cannot attempt to or decide not to conceive immediately after surgery may be offered hormone therapy as it does not negatively impact their fertility and improves the immediate outcome of surgery for pain

 

Conditional

In infertile women with endometriosis, clinicians should not prescribe pentoxifylline, other anti-inflammatory drugs or letrozole outside ovulation-induction to improve natural pregnancy rates.

 

Strong

Surgical treatment

 

The GDG recommends that the decision to perform surgery should be guided by the presence or absence of pain symptoms, patient age and preferences, history of previous surgery, presence of other infertility factors, ovarian reserve, and estimated Endometriosis Fertility Index (EFI).

GPS

Operative laparoscopy could be offered as a treatment option for endometriosis-associated infertility in rASRM stage I/II endometriosis as it improves the rate of ongoing pregnancy.

 

Conditional

Clinicians may consider operative laparoscopy for the treatment of endometrioma-associated infertility as it may increase their chance of natural pregnancy, although no data from comparative studies exist.

 

Conditional

Although no compelling evidence exists that operative laparoscopy for deep endometriosis improves fertility, operative laparoscopy may represent a treatment option in symptomatic patients wishing to conceive.

 

Conditional

Assessing the need for assisted reproduction after surgery

 

Women should be counselled of their chances of becoming pregnant after surgery. To identify patients that may benefit from ART after surgery, the Endometriosis Fertility Index (EFI) should be used as it is validated, reproducible and cost-effective. The results of other fertility investigations such as their partner’s sperm analysis should be taken into account.

 

GPS

Medically assisted reproduction

 

IUI with endometriosis

 

In infertile women with rASRM stage I/II endometriosis, clinicians may perform intrauterine insemination (IUI) with ovarian stimulation, instead of expectant management or IUI alone, as it increases pregnancy rates.

 

Conditional

Although the value of IUI in infertile women with rASRM stage III/IV endometriosis with tubal patency is uncertain, the use of IUI with ovarian stimulation could be considered.

 

Conditional

ART in women with endometriosis

 

ART can be performed for infertility associated with endometriosis, especially if tubal function is compromised, if there is male factor infertility, in case of low EFI and/or if other treatments have failed

 

Conditional

A specific protocol for ART in women with endometriosis cannot be recommended. Both GnRH antagonist and agonist protocols can be offered based on patients’ and physicians’ preferences as no difference in pregnancy or live birth rate has been demonstrated

 

Conditional

Women with endometriosis can be reassured regarding the safety of ART since the recurrence rates are not increased compared to those women not undergoing ART.

 

Conditional

In women with endometrioma, clinicians may use antibiotic prophylaxis at the time of oocyte retrieval, although the risk of ovarian abscess formation following follicle aspiration is low.

 

GPS

Medical therapies as an adjunct to MAR

 

The extended administration of GnRH agonist prior to ART treatment to improve live birth rate in infertile women with endometriosis is not recommended, as the benefit is uncertain.

Strong

There is insufficient evidence to recommend prolonged administration of the COC/progestogens as a pre-treatment to ART to increase live birth rates.

 

Conditional

Surgical therapies as an adjunct to MAR

 

Clinicians are not recommended to routinely perform surgery prior to ART to improve live birth rates in women with rASRM stage I/II endometriosis, as the potential benefits are unclear.

Strong

Clinicians are not recommended to routinely perform surgery for ovarian endometrioma prior to ART to improve live birth rates, as the current evidence shows no benefit and surgery is likely to have a negative impact on ovarian reserve.

Strong

Surgery for endometrioma prior to ART can be considered to improve endometriosis-associated pain or accessibility of follicles.

GPS

The decision to offer surgical excision of deep endometriosis lesions prior to ART should be guided mainly by pain symptoms and patient preference as its effectiveness on reproductive outcome is uncertain due to lack of randomised studies

Strong

Non-medical management strategies for infertility

 

No recommendation can be made to support any non-medical interventions (nutrition, Chinese medicine, electrotherapy, acupuncture, physiotherapy, exercise, and psychological interventions) to increase fertility in women with endometriosis. The potential benefits and harms are unclear.

 

 

GPS

Fertility Preservation

 

In case of extensive ovarian endometriosis, clinicians should discuss the pros and cons of fertility preservation with women with endometriosis. The true benefit of fertility preservation in women with endometriosis remains unknown

Strong

Impact of endometriosis on pregnancy and pregnancy outcome

 

Patients should not be advised to become pregnant with the sole purpose of treating endometriosis, as pregnancy does not always lead to improvement of symptoms or reduction of disease progression.

strong

Complications related directly to pre-existing endometriosis lesions are rare, but probably under-reported. Such complications may be related to their decidualization, adhesion formation/stretching and endometriosis-related chronic inflammation. Although rare, they may represent life-threatening situations that may require surgical management.

GPS

Clinicians should be aware that there may be an increased risk of first trimester miscarriage and ectopic pregnancy in women with endometriosis.

Strong

Clinicians should be aware of endometriosis-associated complications in pregnancy, although these are rare. As these findings are based on low/moderate quality studies, these results should be interpreted with caution and currently do not warrant increased antenatal monitoring or dissuade women from becoming pregnant.

Strong

Endometriosis recurrence

 

Prevention of endometriosis recurrence

When surgery is indicated in women with an endometrioma, clinicians should perform ovarian cystectomy, instead of drainage and electrocoagulation, for the secondary prevention of endometriosis-associated dysmenorrhea, dyspareunia, and non-menstrual pelvic pain. However, the risk of reduced ovarian reserve should be taken into account

 

 

Strong

Clinicians should consider prescribing the postoperative use of a levonorgestrel-releasing intrauterine system (52 mg LNG-IUS) or a combined hormonal contraceptive for at least 18–24 months for the secondary prevention of endometriosis-associated dysmenorrhea

 

Strong

After surgical management of ovarian endometrioma in women not immediately seeking conception, clinicians are recommended to offer long-term hormone treatment (e.g. combined hormonal contraceptives) for the secondary prevention of endometrioma and endometriosis-associated related symptom recurrence.

 

Strong

For the prevention of recurrence of deep endometriosis and associated symptoms, long-term administration of postoperative hormone treatment can be considered

 

Conditional

Long-term administration of progestogen may reduce the recurrence of ovarian endometriotic cysts.

Conditional

Treatment of recurrent endometriosis

Any hormone treatment or surgery can be offered to treat recurring pain symptoms in women with endometriosis

 

Conditional

Adolescent Endometriosis

 

Clinical symptoms:

In adolescents, clinicians should take a careful history and consider the following symptoms as suggestive of the presence of endometriosis:

-chronic or a-cyclical pelvic pain, particularly combined with nausea, dysmenorrhea, dyschezia, dysuria, dyspareunia

-cyclical pelvic pain

 

 

Strong

Clinical examination

In case of virgin written informed consent from the patient and her parents before rectal examination

 

 

GPS

The recommendations for clinical examination in adults can be applied.

GPS

Imaging

In case of virgin written informed consent from the patient and her parents before rectal u/s

 

 

GPS

Pelvic imaging with ultrasonography, regardless of findings on pelvic examination, also should be considered during evaluation for secondary dysmenorrhea.

 

GPS

Transvaginal ultrasound is recommended to be used in adolescents in whom it is appropriate non virgin, as it is effective in diagnosing ovarian endometriosis.

 

Strong

 

If a transvaginal scan is not appropriate, MRI, trans abdominal, trans-perineal, or trans rectal scan may be considered.

 

Conditional

Laboratory parameters

Serum biomarkers (e.g., CA-125) are not recommended for diagnosing or ruling out endometriosis in adolescents.

Strong

Diagnostic laparoscopy

In adolescents with suspected endometriosis where imaging is negative and imperical medical treatments (with NSAIDs and/or hormonal contraceptives) have not been successful, diagnostic laparoscopy may be considered.

 

Conditional

The appearance of endometriosis may be different in an adolescent than in an adult woman. In adolescents, endometriotic lesions are typically clear or red and can be difficult to identify for gynecologists unfamiliar with endometriosis in adolescents.

 

GPS

If a laparoscopy is performed, clinicians may consider taking biopsies to confirm the diagnosis histologically, although negative histology does not entirely rule out the disease.

 

 

Strong

Medical treatment

Nonsteroidal anti-inflammatory drugs should be the mainstay of pain relief for adolescents with endometriosis.

 

GPS

In adolescents with severe dysmenorrhea and/or endometriosis-associated pain, Clinicians should prescribe hormonal contraceptives or progestogens

 

Strong

In adolescents with laparoscopically confirmed endometriosis and associated pain in whom hormonal contraceptives or progestogen therapy failed, clinicians may consider prescribing GnRH agonists combined with add-back therapy for up to 1 year, as they are effective and safe.

 

Conditional

If GnRH agonist treatment is considered, it should be used only after careful consideration and discussion of potential side effects and potential long-term health risks with a practitioner in a secondary or tertiary care setting

 

GPS

Combined medical and surgical treatment.

In adolescents with endometriosis, clinicians should consider postoperative hormone therapy, as this may suppress recurrence of symptoms

 

Strong

Menopause and Endometriosis

 

Treatment of endometriosis in postmenopausal women

 

Clinicians may consider surgical treatment for postmenopausal women presenting with signs of endometriosis and/or pain to enable histological confirmation of the diagnosis of endometriosis

conditional

Clinicians should acknowledge the uncertainty towards the risk of malignancy in postmenopausal women. If a pelvic mass is detected, the work-up and treatment should be performed according to national oncology guidelines

GPS

For postmenopausal women with endometriosis-associated pain, clinicians may consider aromatase inhibitors as a treatment option especially if surgery is not feasible.

 

Conditional

Menopausal symptoms in women with a history of endometriosis

 

Clinicians may consider combined menopausal hormone therapy (MHT) for the treatment of postmenopausal symptoms in women (both after natural and surgical menopause) with a history of endometriosis

Conditional

Clinicians should avoid prescribing estrogen-only regimens for the treatment of vasomotor symptoms in postmenopausal women with a history of endometriosis, as these regimens may be associated with a higher risk of malignant transformation

 

Strong

Clinicians should continue to treat women with a history of endometriosis after surgical menopause with combined estrogen-progestogen at least up to the age of natural menopause.

 

GPS

Menopause-related major health concerns in women with endometriosis

 

Clinicians should be aware that women with endometriosis who have undergone an early bilateral salpingo-oophorectomy as part of their treatment have an increased risk of diminished bone density, dementia, and cardiovascular disease. It is also important to note that women with endometriosis have an increased risk of cardiovascular disease, irrespective of whether they have had an early surgical menopause

 

 

GPS

Extra pelvic endometriosis

 

Clinicians should be aware of symptoms of extra-pelvic thoracic endometriosis, such as cyclical shoulder pain, cyclical spontaneous pneumothorax, cyclical cough, or nodules which enlarge during menses.

GPS

It is advisable to discuss diagnosis and management of extra-pelvic & thoracic endometriosis in a multidisciplinary team in a center with sufficient expertise

GPS

For abdominal extra-pelvic endometriosis, surgical removal is the preferred treatment, when possible, to relieve symptoms. Hormone treatment may also be an option when surgery is not possible or acceptable

 

Conditional

Asymptomatic endometriosis

 

Treatment

Clinicians should inform and counsel women about any incidental finding of endometriosis

 

GPS

Clinicians should not routinely perform surgical excision/ablation for an incidental finding of asymptomatic endometriosis at the time of surgery

 

Strong

Clinicians should not prescribe medical treatment in women with incidental finding of endometriosis

 

Strong

Monitoring

Routine ultrasound monitoring of asymptomatic endometriosis can be considered.

 

 

Conditional

Primary prevention of endometriosis

 

Although there is no direct evidence of benefit in preventing endometriosis in the future, women can be advised of aiming for a healthy lifestyle and diet, with reduced alcohol intake and regular physical activity

Conditional

The usefulness of hormonal contraceptives for the primary prevention of endometriosis is uncertain

Conditional


 

Clinical Guideline · 07

Recommendations on The Clinical Interventions For The Prevention of The Primary Cesarean Section

last update: 4 August 2025”
Download Guideline
– Executive Summary193 بندعرض التوصيات
“last update: 4 August  2025”                                                                                                     Download Guideline
 

– Executive Summary

 

This guideline offers evidence-based recommendations on the clinical interventions for the safe prevention of the primary cesarean section. The recommendations are intended to provide healthcare professionals caring for pregnant women with practical guidance on how to safely avoid the primary cesarean section.

 

List of Recommendations

 

Recommendation

Strength of Recommendation

1. Measures During ANC and Before Labor

 

1.1. Planning of Birth

 

1.1.1. Discuss the benefits and risks of both caesarean and vaginal birth with women, taking into account their circumstances, concerns, priorities and plans for future pregnancies. (See Appendix I)

GPS

 

1.1.2. Fetal presentation should be assessed and documented beginning at 36 0/7 weeks of gestation to guide the plan of management.

GPS

 

1.2. Breech Presentation & Other Fetal Malpresentation

 

1.2.1. Offer women who have an uncomplicated singleton breech pregnancy after 36+0 weeks, external cephalic version by an experienced obstetrician, unless:

➡️ the woman is in established labor

➡️ there is fetal compromise

➡️ the woman has ruptured membranes or vaginal bleeding

➡️ the woman has any other medical conditions (for example, severe hypertension) that would make external cephalic version inadvisable.

Conditional

 

1.2.2. Before carrying out a caesarean birth for an uncomplicated singleton breech pregnancy, carry out an ultrasound scan to check that the baby is in the breech position. Do this as late as possible before the caesarean birth procedure.

GPS

 

1.3. Suspected Fetal Macrosomia

 

1.3.1 Cesarean delivery to avoid potential birth trauma should be limited to estimated fetal weights of at least 4500 g in women without diabetes and at least 4000 g in women with diabetes.

GPS

 

1.4. Twin Gestations

 

1.4.1. Perinatal outcomes for twin gestations in which first twin is in cephalic presentation are not improved by cesarean delivery. Thus, women with either cephalic/cephalic presenting twins or cephalic/non-cephalic presenting twins should be counseled to attempt vaginal delivery.

Strong

 

1.5. Predicting Caesarean Birth for Cephalopelvic Disproportion

 

1.5.1. Do not use pelvimetry for decision making about mode of birth.

Strong

 

1.5.2. Do not use the following for decision making about mode of birth, as they do not accurately predict cephalopelvic disproportion:

➡️ maternal shoe size

➡️ maternal height

➡️ estimations of fetal size (ultrasound or clinical examination).

GPS

 

1.6. Mother-To-Child Transmission of Hepatitis

 

1.6.1 Hepatitis B virus: Do not offer pregnant women with hepatitis B a planned caesarean birth for this reason alone, as mother-to-baby transmission of hepatitis B can be reduced if the baby receives immunoglobulin and vaccination.

Strong

 

1.6.2 Hepatitis C virus: Do not offer women who are infected with hepatitis C a planned caesarean birth for this reason alone.

Strong

 

1.7. Body Mass Index

 

1.7.1. Do not use a BMI of over 50 kg/m2 alone as an indication for planned caesarean birth.

GPS

 

1.8. Cesarean On Maternal Request

 

1.8.1 If a pregnant woman  with no medical indication for a caesarean birth requests a caesarean birth:

➡️ discuss and explore the reasons for the request

➡️ address concerns they have about the birth as pain and pain relief options

➡️ discuss the overall benefits and risks of CS birth compared with vaginal birth (See Appendix I)

➡️ Document the discussion and the decision taken

GPS

 

1.8.2. Don’t do cesarean section on request without a written informed  consent from the woman indicating that this is a CS on request in absence of a medical or obstetric indication.

GPS

1.9. Head Engagement in A Primigravida

 

1.9.1 Non-engagement of the head in a primigravida should not be considered as an only factor requiring cesarean birth.

GPS

2. Measures During Labor

 

2.1. Induction of Labor

 

2.1.1. Before 41 0/7 weeks of gestation, induction of labor generally should be performed based on maternal and fetal medical indications. Inductions at ≥ 41 0/7 weeks of gestation should be performed to reduce risk of cesarean delivery and risk of perinatal morbidity and mortality.

Strong

 

2.1.2 Cervical ripening methods should be used when labor is induced in women with unfavorable cervix.

 

Strong

 

2.2. First Stage of Labor: Latent Phase

 

2.2.1 The use of the following definition of the latent phase of the first stages of labor is recommended for practice: The latent first stage is a period of time characterized by:

➡️ Painful uterine contractions and

➡️ variable changes of the cervix, including some degree of effacement and slower progression of dilatation up to 5 cm for first and subsequent labors.

Strong

 

2.2.2 A prolonged latent phase (eg, >20 hours in nulliparous women and >14 hours in multiparous women) should not be an indication for cesarean delivery.

Strong

 

2.2.3. These durations are not recommended as an indication for intervention when maternal and fetal condition are reassuring.

Strong

 

2.2.4. If slow progress is suspected, assess to identify:

➡️ Developing complications

➡️ Reassuring maternal and fetal condition

➡️ Emotional and physical needs

Strong

 

2.3. First Stage of Labor: Active Phase

 

2.3.1. The use of the following definition of the active phase of the first stages of labor is recommended for practice:

➡️ The active first stage is a period of time characterized by regular painful uterine contractions, and a substantial degree of cervical effacement and more rapid cervical dilatation from 5 cm until full dilatation for first and subsequent labors.

Strong

 

2.3.2 Use a partogram with a 4-hour action line to monitor progress of women in spontaneous labor with an uncomplicated singleton pregnancy at term starting in the active phase, to reduce the likelihood of caesarean birth.

GPS

 

2.3.3. Regarding the Partogram: A minimum cervical dilatation rate of 1 cm/hour throughout active first stage is not recommended for identification of normal labor progression and a slower than 1-cm/hour cervical dilatation rate alone should not be a routine indication for obstetric intervention.

GPS

 

2.3.4. A cervical dilatation of 0.5 cm per hour (2 cm in 4 hours) is considered normal in the active phase.

GPS

 

2.3.5. Protracted labor (slower progress than is usual) is diagnosed when in:

· Nulliparous women: a cervical dilatation of <  2 cm in 4 hours is found

· Multiparous women: a cervical dilatation of < 2 cm in 4 hours or a slowing in the progress of labor

If delay is suspected, check descent and rotation of the baby’s head and changes in the strength, duration and frequency of uterine contractions (uterine atony).

GPS

 

2.3.6. For women with intact membranes in whom delay in the established first stage of labor is confirmed:

➡️ consider amniotomy if membranes are intact,

➡️ oxytocin if inertia was diagnosed and

➡️ a repeat vaginal examination 2 hours later.

➡️ If oxytocin is used, ensure that the time between increments of the dose is no more frequent than every 30 minutes and increase oxytocin until there are 4–5 contractions in 10 minutes.

➡️ If cervical dilatation has increased by less than 2 cm after 4 hours of oxytocin, review is required to assess the need for caesarean section.

GPS

 

2.3.7. Labor may not naturally accelerate until a cervical dilatation threshold of 5 cm is reached. Therefore, the use of medical interventions to accelerate labor and birth (such as oxytocin augmentation or caesarean section) before this threshold is not recommended, provided fetal and maternal conditions are reassuring.

Strong

 

2.3.8. Arrest in labor (complete cessation of progress) is diagnosed at cervical dilatation of 6 cm or more with ruptured membranes and no or limited cervical change for 4 hours of adequate contractions.

Strong

 

2.3.9. Cesarean delivery for active-phase arrest in first stage of labor should be reserved for women ≥ 6 cm of dilation with ruptured membranes who fail to progress despite 4 hours of adequate uterine activity

Strong

 

2.4. Fetal Heart Rate Monitoring

 

2.4.1. Intermittent auscultation of the fetal heart rate with either a Doppler ultrasound device or Pinard fetal stethoscope is recommended for healthy pregnant women in labor.

Strong

 

2.4.2. Standardization of protocol of the intermittent auscultation is important for health care planning and medico-legal purposes and, therefore, the WHO adopted the following protocol:

· Interval: Auscultate every 15–30 minutes in active first stage of labor, and every 5 minutes in the second stage of labor.

· Duration: Each auscultation should last for at least 1 minute; if the FHR is not always in the normal range (i.e. 110–160 bpm), auscultation should be prolonged to cover at least three uterine contractions.

· Timing: Auscultate during a uterine contraction and continue for at least 30 seconds after the contraction

· Recording: Record the baseline FHR (as a single counted number in beats per minute) and the presence or absence of accelerations and decelerations

Strong

 

2.5. Second stage of labor

 

2.5.1. The use of the following definition and duration of the second stage of labor is recommended for practice: The second stage is the period of time between full cervical dilatation and birth of the baby, during which the woman has an involuntary urge to bear down, as a result of expulsive uterine contractions.

STRONG

 

2.5.2. The duration of the second stage varies from one woman to another:

➡️ In first labor, birth is usually completed within 2 hours

➡️ In subsequent labors, birth is usually completed within 1 hour.

GPS

 

2.5.3. Before diagnosing arrest of labor in second stage, if maternal and fetal conditions permit, allow for:

➡️ At least 1 h of pushing in multiparous women

➡️ At least 2 h of pushing in nulliparous women

Longer durations may be appropriate on individualized basis (e.g., with use of epidural analgesia or with fetal malposition) as long as maternal and fetal conditions are reassuring and progress is being documented.

Strong

 

2.5.4. Delay in active second stage is diagnosed when:

➡️ In nulliparous woman (any of): either insufficient flexion/rotation/descent within 1 hour or the second stage duration is > 2 hours.

➡️ In multiparous woman (any of): either insufficient flexion/rotation/descent within 30 minutes or the second stage duration is > 1 hour.

Longer durations may be appropriate where maternal and fetal condition is optimal.

GPS

 

2.5.5. A specific absolute maximum length of second stage (passive plus active) has not been identified. Rather than rigid time limits, base decision-making on continuing assessment of:

➡️ Maternal physical and emotional condition

➡️ Fetal condition

➡️ Progress of labor

➡️ Maternal preferences

GPS

 

2.5.6. Operative vaginal delivery in second stage of labor by experienced and well-trained physicians should be considered safe, acceptable alternative to cesarean delivery. Training in, and ongoing maintenance of, practical skills related to operative vaginal delivery should be encouraged.

Strong

 


 

 

 

Clinical Guideline · 08

Primary Postpartum Hemorrhage

last update: 17 December 2025”
Download Guideline
– Executive Summary412 بندعرض التوصيات
“last update: 17 December  2025”                                                                          Download Guideline
 

– Executive Summary

 

This guideline offers evidence-based recommendations on prevention and management of postpartum hemorrhage. The recommendations are intended to provide healthcare professionals with practical guidance on risk prevention, treatment interventions and improving health outcomes for cases of postpartum hemorrhage.

List of Recommendations

Recommendation

Strength

1. PREVENTION OF POSTPARTUM HEMORRHAGE

 

1.1 Risk Assessment:

 

1.1.1. Risk factors for PPH may present antenatally or intrapartum; care plans must be modified as and when risk factors arise.

GPS

1.1.2. Clinicians must be aware of risk factors for PPH and should take these into account when counselling women about place of delivery.

GPS

1.1.3. Women with known risk factors for PPH should only be delivered in a hospital with a blood bank on site.

Strong

1.1.4. An individualized risk assessment for postpartum hemorrhage should be documented upon arrival to a labor unit and updated throughout labor and delivery.

Strong

1.2 Risk Factors

 

1.2.1 Consider the following antenatal risk factors for PPH

·       Age > 35

·       Obesity (BMI >35)

·       More than 3 prior births

·       Previous PPH

·       Previous Cesarean section with placenta previa or PAS

·       Previous uterine surgery

·       Presence of uterine fibroid

·       Multiple pregnancy

·       Polyhydramnios

·       Fetal macrosomia

·       Anemia

·       Known coagulopathy or other bleeding disorders

GPS

1.2.2. Consider the following intrapartum risk factors for PPH

·       Oxytocin use in labor

·       Prolonged second stage

·       Prolonged third stage

·       Retained placenta

·       Manual removal of placenta

·       Assisted vaginal birth

·       Cesarean section whether elective or emergency

·       Perineal trauma

·       Uterine rupture

·       General anaesthesia

·       Infection

·       Non-cephalic presentation

·       Precipitate labor

GPS

1.3. Antenatal Risk Management

 

1.3.1. Antenatal anemia

 

1.3.1.1. Antenatal anemia should be investigated and treated appropriately as this may reduce the morbidity associated with PPH.

Strong

1.3.2. Maternal blood disorders

 

 1.3.2.1. Involve specialist physician to:

·       Optimize coagulation profile prior to birth

·       Advise on birth options (e.g. mode of birth)

1.3.2.2. Seek anesthetic opinion regarding options for analgesia during labor and birth

Strong

1.3.3. Abnormal placentation

 

1.3.3.1. Determine placental site and if abnormal placental adherence is suspected (PAS):

·       Refer to a center equipped for placenta accreta management.

·       Involve multidisciplinary team including urologist, general surgeon, vascular surgeon,  hematologist, senior anaesthetist and ICU specialist in preoperative planning.

Strong

1.4. Intrapartum Risk Management

 

1.4.1. Management of third stage of labor

The use of uterotonics for prevention of PPH during the third stage of labor

is recommended for all births.

Strong

1.4.2. Cord clamping:

1.4.2.1. Late cord clamping (performed approximately 1 to 3 minutes after birth) is recommended for all births while initiating simultaneous essential newborn care.

1.4.2.2. Early cord clamping (<1 minute after birth) is not recommended unless the neonate is asphyxiated and needs to be moved immediately for resuscitation.

Strong

1.4.3. Controlled cord traction:

1.4.3.1 Consider Controlled cord traction (CCT) as part of active/modified active management of third stage as it may.

Strong

1.4.3.2. Providers employing CCT should only do so after signs of placental separation, and traction should be performed with uterine contraction as these measures reduce the risk of uterine inversion, cord avulsion, and partial detachment of the placenta.

Strong


 

1.5. Prophylactic Uterotonics:

 

1.5.1. Oxytocin:

1.5.1.1. In most circumstances, oxytocin is the prophylactic uterotonic of choice.

1.5.1.2 For vaginal birth

·       If vaginal birth with IV access: Oxytocin 10 IU IV injected slowly over 3–5 minutes is recommended in preference to IM

·       If vaginal birth without IV access: Oxytocin 10 IU IM

·       To be transferred ransfer to rational: When compared with IM, IV oxytocin reduces the risk of PPH, need for blood transfusion 60-62 and incidence of retained placenta with no significant difference in side effects (e.g. hypotension and tachycardia) between routes 60,61

1.5.1.3. For CS birth:

·       Oxytocin 5 IU IV over 1–2 minutes

·       Monitor for hemodynamic impact

·       Avoid rapid IV bolus administration

1.5.1.4. If cardiovascular compromise exists (e.g. hypovolemia, shock, cardiac disease), use caution with IV administration. Rational it may result in transient hemodynamic instability 61, 65

Strong

1.5.2. Ergometrine:

1.5.2.1 Ergometrine can be given IM or, in life-saving circumstances, as a slow IV injection.

1.5.2.2. Ergometrine should not be used in patients with essential or gestational hypertension, or in patients on HIV protease inhibitors.

1.5.2.3. Though undisputedly extremely effective, potential adverse effects limit ergometrine to a second-line agent.

Conditional

1.5.3. Carbetocin:

1.5.3.1. Routinely use oxytocin in preference to carbetocin if vaginal birth and cold-chain storage of oxytocin can be guaranteed (e.g. hospital setting).

1.5.3.2. If vaginal birth and cold-chain storage of uterotonics cannot be guaranteed:

·       Carbetocin is an effective alternative uterotonic

·       IM is preferred route of administration

1.5.3.2. If CS birth under regional anesthetic: IV carbetocin may be considered as a cost effective uterotonic

1.5.3.3. If CS birth under general anesthetic: Carbetocin is not recommended due to insufficient evidence.

1.5.3.4. If used: used as a single dose only, not for repeated use

Conditional

1.5.4. Misoprostol:

1.5.4.1. Not recommended if alternative injectable uterotonics are available

1.5.4.2. Use only if no other injectable uterotonic is available (e.g. due to unexpected birth in low resource setting or if storage conditions for uterotonics are inadequate).

1.5.4.3. The dose is 600 micrograms orally or sublingual single dose immediately after birth

1.5.4.4. If in a low resource setting with limited PPH treatment capability, consider use if:

·       an injectable uterotonic has been administered AND

·       continued bleeding is anticipated and/or blood loss is estimated to be greater than or equal to 350 mL  

Conditional

1.6. Tranexamic Acid (TXA) For Prophylaxis in High Risk Women

 

1.6.1. Tranexamic acid can be used as a prophylactic agent as an adjunct to uterotonics in patients at high risk for postpartum hemorrhage.

1.6.2. Use TXA within 3 hours of birth of the baby in a fixed dose of 1 g in 10 mL IV over 10 minutes (100 mg/min i.e. 1 ml /minute)

Strong

1.7. Immediate Postpartum Risk Management

 

1.7.1. Uterine massage:

Sustained uterine massage is not recommended as an intervention to prevent PPH in women who have received prophylactic oxytocin.

GPS

1.7.2. Uterine tonus assessment:

Postpartum abdominal uterine tonus assessment for early identification of uterine atony is recommended for all women.

Strong

1.7.3. Nipple stimulation & breast feeding:

Nipple stimulation and/or early breastfeeding may increase uterine activity but has not been shown to reduce bleeding or incidence of PPH.

GPS

1.7.4. Observation for women with risk factors in the first 2 hours postpartum:

·       Vital signs: Respiratory rate, pulse rate, and blood pressure, every 15-30 minutes in the first hour and every 30 minutes in the second hour.

·       Blood Loss every 15-30 minutes by visualizing the labia and perineum and be alert for slow steady trickle.

·       Temperature every 30 minutes

·       Uterine tonus assessment

·       Urine output: after the first 2 hours

·       After the first 2 hours continue as clinically indicated

Strong

2. RECOGNITION OF PPH

 

2.1. General Principles In Diagnosis of PPH

 

2.1.1 Early recognition of postpartum hemorrhage (before deterioration in vital signs) is recommended and should be the goal in order to improve outcomes.

Strong

2.1.2. Clinical signs and symptoms of hypovolemia should be included in the assessment of PPH. However, clinicians should be aware that the signs of hypovolemic shock become less sensitive in pregnancy.

Strong

2.1.4. Consider initiation of response to PPH when there is excessive bleeding in the first 24 hours post birth, judged clinically, or through estimation of blood loss volume (> 500 ml after VD or 1000ml after CS), or changes in the hemodynamic state.

Strong

2.2 Visual Assessment of The Amount of Postpartum Blood Loss

 

2.2.1. Visual estimation of blood loss is always subjective and can be imprecise and often leads to underestimation of large volumes or overestimation of small volumes

2.2.2. When conducting visual assessment of blood loss, consider the volume, nature and speed of blood loss.

2.2.3. Simulated scenarios and pictorial guides may improve staff accuracy  

Conditional

2.3. Quantitative Measurement of The Amount of Postpartum Blood Loss

 

2.3.1 Consider that quantitative measurement, provides a more accurate assessment of blood loss when compared with visual estimation.

2.3.2. Consider measurement of blood loss by blood collection drapes for vaginal deliveries,5,10 or the weighing of swabs and weigh blood-soaked items (e.g. linen, pads, swabs, drapes) to quantify volume.5,60 If weighing, 1 gram is equivalent to 1 mL blood loss.

Conditional

2.4. Diagnosis of PPH & Assessment of Hemodynamic Compromise

 

2.4.1. PPH can be minor (500–1000 ml blood loss) or major (more than 1000 ml blood loss). The condition becomes worse if the patient lost >2000 mL of blood.

2.4.2. Diagnose minor PPH (blood loss 500-1000 mL) if there are: 

·       Normal blood pressure

·       Mild increase in heart rate (but <100 beats/minute)

·       Palpitation

·       Lightheadedness

2.4.3. Diagnose major PPH (blood loss from 1000-2000 mL) if there are: 

·       Drop of blood pressure below the original average of the patient

·       Tachycardia (≥ 100 beats/minute)

·       Sweating

·       Weakness

GPS

2.4.4. Signs of hemodynamic compromise are a late indicator of PPH and may not be evident until large volumes of blood are lost (e.g. up to 25% of total blood volume or greater than 1500 mL).

2.4.5. Don’t wait for the following to diagnose major PPH as blood loss is already >2000 mL and the condition would be severe enough to be of poorer prognosis:

·       Systolic blood pressure drops below 70-80 mmHg 

·       Tachycardia (120-140 beats/minute)

·       Restlessness, confusion and pallor

·       Oliguria

2.4.6. Conversely, compromise may occur earlier in women with:

·       Gestational hypertension with proteinuria

·       Anemia

·       Dehydration

·       Small stature

·       Cardiac disease

Strong

3. RESPONDING TO AND MANAGEMENT OF PPH

 

3.1. General Principles In Responding To PPH

 

3.1.1. Bleeding after labor is an emergency and responding to it should not be delayed and should start as early as possible and goes hand in hand with the rest of management (Communication with the patient, senior staff, resuscitation investigation, and monitoring).

GPS

3.1.2. Use an approach that involves maintaining hemodynamic stability while simultaneously identifying and treating the cause of blood loss.

Strong

3.1.3. The urgency and measures undertaken to resuscitate and arrest hemorrhage need to be tailored to the amount of blood loss (which is usually underestimated), the patient general condition, and the degree of shock.

Strong

3.1.4 The GDG recommends adoption of the EMOTIVE bundle (Early detection, Massage, Oxytocics, Tranexamic acid, IV fluids, Examination & Escalation) as the standard first-response protocol for all cases of postpartum hemorrhage. Initiate all components within 15 minutes of PPH diagnosis to ensure rapid, standardized, and evidence-based management, with ongoing monitoring and escalation as needed, see Appendix II.

Strong

3.2. Communication And Multidisciplinary Care:

 

3.2.1. Communication with the patient and her birthing partner is important, and clear information of what is happening should be given from the outset.

3.2.2. Relevant staff with an appropriate level of expertise should be alerted of PPH.

3.2.3. The first-line obstetric and anesthetic staff should be alerted when women present with minor PPH (blood loss 500–1000 ml) without clinical shock

3.2.4. A multidisciplinary team involving senior members of staff should be called to attend to women with major PPH (blood loss of more than 1000 ml) and ongoing bleeding or clinical shock

GPS

3.3. Responding To & Managing Minor PPH

 

3.3.1. Measures for minor PPH (blood loss 500–1000 ml) without clinical shock:

·       Establish IV access: 2 wide bore IV cannulas (Orange 14G & Grey 16G) are to be inserted. 14G for fluid and blood replacement & 16G for pharmacologic therapy 

·       Urgent venipuncture and obtain 20 ml of blood for:

o   Grouping & cross-matching

o   Full blood count

o   Coagulation screen, including fibrinogen, if available

·       Pulse, respiratory rate and blood pressure recording every 15 minutes

·       Commence warmed crystalloid infusion.

·       If bleeding is rapid and patient continues to bleed, consider starting the full protocol for major PPH.

·       In minor PPH, there are no firm criteria for initiating red cell transfusion. The decision to provide blood transfusion should be based on both clinical and hematological assessment.

GPS

3.4. Identification of The Cause (the 4Ts)

 

3.4.1. If blood loss after delivery seems increased, start the measures of minor PPH and immediately assess for the Tone of the uterus, the presence of Trauma, any retained Tissue or Thrombin activity.

·       Tone: massage the fundus to see whether the uterus is atonic or well contracted.

·       Tissue: retained placental fragment. Inspect the placenta for a missing part. Also suspect retained placental fragment or pieces of membranes as a cause if there is atonic fundus unresponsive to uterotonics.

·       Trauma: if fundus is well contracted, blood clotting is ok and no placental remnants, explore birth canal for improperly repaired birth tract injuries.

·       Thrombin: The fundus is contracted (may be atonic) and the blood is not clotting.

·       Other unknown causes: if all of the above is normal, assess for uterine rupture/ inversion, concealed bleeding (e.g. vault hematoma, internal hemorrhage after CS) and non-genital causes (e.g. subcapsular liver rupture).

GPS

3.5. Responding To & Managing Major PPH

 

3.5.1. Full protocol for major PPH (blood loss greater than 1000 ml) and continuing to bleed or clinical shock:

·       A and B: assess Airway and Breathing

·       C – evaluate Circulation

·       Position the patient flat

·       Insert two peripheral cannulas (14 gauge) if not inserted before

·       Immediately draw 20 mL of blood for:

o   Cross-matching (4 units of blood minimum)

o   Full blood count

o   Coagulation screen (PT, INR, aPTT including fibrinogen, if available)

o   Chemistry profile (Serum Creatinine, SGOT, SGPT, Albumin, LDH, Blood Sugar)

·       Keep the woman warm using appropriate available measures

·       Transfuse blood as soon as possible.

·       Until blood is available, infuse up to 3.5 L of warmed crystalloids as Lactated Ringer’s (1–2 mL for every 1 mL of blood loss)2

·       Stop fluid once blood is ready.

·       The best equipment available should be used to achieve rapid warmed infusion of fluids.

·       Special blood filters should not be used, as they slow infusions.

·       If actively bleeding, transfuse early and do not wait unnecessarily for laboratory results and use clinical assessment as the main determinant

3.5.2. Blood transfusion:

·       3.5.2.1. If actively bleeding, transfuse early, do not wait unnecessarily for laboratory results. The clinical picture should be the main determinant of the need for blood transfusion and time should not be unnecessarily spent awaiting laboratory results.

·       3.5.2.2. Packed RBCs:

o   Provide emergency blood (Packed RBCs) with immediate issue of group O, rhesus D (RhD)-negative, with a switch to group-specific blood as soon as feasible.

o   Single Hb/hematocrit estimations may be misleading and can lead to delays in initiating red cell transfusion, serial measurements may be helpful to monitor ongoing progress.

·       3.5.2.2. Transfusion of FFP:

o   Administration of FFP should be guided by coagulation profile test results and whether bleeding is continuing.

o   But if coagulation profile results are not available and bleeding is continuing, after 4 units of red blood cells, 4 units of FFP should be infused until test results are known.

o   If coagulation profile results are not available, early FFP should be considered for conditions with a suspected coagulopathy, such as placental abruption or amniotic fluid embolism, or where detection of PPH has been delayed.

o   If prothrombin time/activated partial thromboplastin time is more than 1.5 times normal and hemorrhage is ongoing, more units of FFP are likely to be needed to correct coagulopathy.

·       3.5.2.3. Clinicians should be aware that these blood components must be ordered as soon as a need for them is anticipated, as there will always be a short delay in supply because of the need for thawing.

3.5.3. Cryoprecipitate For Fibrinogen Replacement

·       A plasma fibrinogen level of greater than 2 g/l should be maintained, if test is available, during ongoing PPH.

·       Cryoprecipitate should be used for fibrinogen replacement.

·       Physician should be aware that fibrinogen below 3 g/l and especially below 2 g/l is associated with progression of bleeding, increased RBC and blood component requirements, and the need for invasive procedures.

3.5.4. Transfusion of platelets

·       During PPH, platelets should be transfused when the platelet count is less than 75 × 109/l (75000 / mm3) based on laboratory monitoring.

·       The platelets should ideally be group compatible. RhD-negative women should receive RhD-negative platelets.

3.5.5. Use Continued Resuscitation with lab-guided replacement to maintain the following lab parameters:

·       Hb greater than 8 gm%

·       Platelet count greater than 50 × 109 /l (50000/mm3)

·       Prothrombin time (PT) less than 1.5 times normal

·       Activated partial thromboplastin time (APTT) less than 1.5 times normal 

·       Fibrinogen level greater than 2 g/l.

GPS

3.5.5. Tranexamic acid (TXA)

3.5.5.1. Tranexamic acid can be used in all patients as an adjunct to uterotonics in the setting of postpartum hemorrhage regardless of whether the bleeding is due to genital tract trauma or other causes.

3.5.5.2. Give TXA as early as possible, ideally within 3 hours of birth, in a fixed dose of 1 g in 10 mL (100 mg/mL) IV at 1 mL per minute (i.e., over 10 minutes).

3.5.5.3. A second dose of 1 g IV may be administered if bleeding continues after 30 minutes of the first dose or for bleeding that stops but restarts within 24 hours of completing the first dose.

Strong

4. MONITORING AND INVESTIGATIONS IN MAJOR PPH

 

4.1 Immediate venipuncture (20 ml) for:

·       Cross-matching (4 units of Packed RBCs minimum)

·       FBC

·       Coagulation screen (PT, INR, aPTT including fibrinogen, if available)

·       Chemistry profile (Serum Creatinine, SGOT, SGPT, Albumin, LDH, Blood Sugar)

·        Repeat as necessary

4.2 Continuous pulse, blood pressure and respiratory rate recording (preferably using oximeter, electrocardiogram and automated blood pressure recording when available) and Monitor temperature every 15 minutes.

4.3.         Foley’s catheter to monitor urine output

4.4.         Documentation of fluid balance, blood, blood products and procedures.

4.5.         Consider transfer to intensive therapy unit once the bleeding is controlled or monitoring at high dependency unit on delivery suite, if appropriate.

4.6.         Consider objective scoring system for monitoring as the MEOWS Score (see Appendix II)

GPS

5. ROLE OF THE ANESTHETIST IN THE MANAGEMENT OF PPH

 

The management of PPH requires a multidisciplinary approach: Allow the anesthetist to play a crucial role in maintaining hemodynamic stability and, in determining and administering the most appropriate method of anesthesia.

Strong

6. PAIN MANAGEMENT

 

Consider pain relief requirements during initial resuscitation and all subsequent treatments

GPS

7. PHARMACOLOGICAL AND MECHANICAL STRATEGIES IN MANAGEMENT OF PPH

 

7.1. Clinicians should be prepared to use a combination of pharmacological, mechanical and surgical methods to arrest PPH. These methods should be directed towards the causative factor.

Strong

7.2. When uterine atony is perceived to be a cause of the bleeding, then a sequence of pharmacological and mechanical measures (in the form of uterine massage and urinary bladder catheterization) should be instituted until the bleeding stops.

Strong

7.3 Stopping the bleeding should not be delayed and should start as early as possible and goes hand in hand with the rest of management above (Communication and multidisciplinary approach, Resuscitation, Investigation, and Monitoring)

GPS

7.4. The most common cause of primary PPH is uterine atony. The initial management of PPH should, therefore, involve measures to stimulate myometrial contractions. Thus, mechanical and pharmacological measures should be instituted/administered as needed.

7.5.         Palpate the uterine fundus and rub it to stimulate contractions and expel its contents (‘rubbing up the fundus’)

7.6.         Ensure that the bladder is empty (Foley catheter & leave in place)

7.7 First line pharmacological therapy for uterine atony (Oxytocin):

·       Give oxytocin 5 IU IV over 1-2 minutes (even if had the prophylactic dose before). The dose may be repeated, only once, after five minutes but consider the maximum dose for IV oxytocin which is 10 IU IV.

·       Rapid IV bolus administration may cause hypotension, tachycardia, arrhythmia and myocardial ischemia.

·       Continue with oxytocin IV infusion 40 IU in 500 mL of either 0.9% sodium chloride (saline) or compound sodium lactate (Ringer’s lactate) at a rate of 5-10 IU/hour via:

o   Using ordinary IV line about adjust it to deliver 20-40 drop/minute

o   Infusion pump, if available, equals to 62.5–125 mL per hour

o   Minimum infusion duration is 2 – 4 hours; use clinical judgement.

·       Oxytocin infusion may be a safer alternative to a bolus dose of oxytocin in some women (e.g. major cardiovascular disorders)

·       If the patient had induction of labor (IOL) with oxytocin, you may use the same infusion but at increased rate.

·       If IV access unavailable or delayed, oxytocin 10 IU IM can be administered

·       If carbetocin has already been given, consider non-oxytocin uterotonic instead

7.8 Supplemental therapy if no adequate response: give the following:

7.8.1.   Ergometrine maleate:

o   0.25 – 0.5 mg IV over 1-2 minutes (dilute 250 micrograms in 5 mL 0.9% sodium chloride) that may be repeated every 5 minutes to a maximum of 1 mg

o   It is contraindicated with retained placenta, severe hypertension, pre-eclampsia, eclampsia severe/persistent sepsis, renal, hepatic, vascular, or cardiac disease

7.8.2.   Misoprostol:

·       Consider misoprostol if alternative uterotonics unavailable or contraindicated (e.g. asthma, hypertension) or if bleeding not effectively controlled with oxytocin.

·       Give 800 mcg sublingual (rapid onset of action with side effects more likely)

·       Or 1000 mcg per rectum (slow absorption but prolonged effect)

·       Consider clinical circumstances when determining optimal route

·       Side effects: Hyperthermia is a common side effect (>38 C is common) and malignant hyperthermia > 40 C has been reported in 1 – 14% of cases

GPS

8. SURGICAL TREATMENTS OF PPH

 

8.1. If pharmacological measures fail to control the hemorrhage, surgical interventions should be initiated sooner rather than later and the most experienced, anesthetist and obstetrician should be called to be involved in the management.

Strong

8.2. Transfer the patient to the operative theatre flat with high-flow oxygen and perform an examination under anesthesia for the exclusion of the presence of remnants (to be evacuated if present) and dealing with any birth tract injuries if found

Strong

8.3. Bimanual Compression: The use of bimanual uterine compression is recommended as a temporary measure until appropriate care is available for the treatment of PPH due to uterine atony after vaginal delivery

Strong

8.4. Intrauterine balloon tamponade:

·       If bimanual compression has been effective consider the use of intrauterine balloon tamponade (e.g. Bakri Balloon) as balloon is an appropriate first-line ‘surgical’ intervention for most women where uterine atony is the only or main cause of hemorrhage after the success of bimanual uterine compression.

·       After insertion, assess blood loss:

·       If bleeding continues, balloon tamponade may be ineffective—review aetiology of PPH, check balloon placement and consider other surgical interventions.

·       If bleeding ceases on insertion, monitor fundal height, uterine cramping and signs of increased blood loss regularly

·       Balloon is left for 6 hours if bleeding stopped and removed in presence of senior staff lest the return of bleeding.

Strong

8.5. If bimanual compression is ineffective or balloon tamponade fail:

·       Consider exploratory laparotomy when less invasive approaches fail to control bleeding. In the setting of a vaginal delivery, it is common to use a midline vertical abdominal incision for laparotomy, to optimize exposure and reduce risk of surgical bleeding. In the setting of cesarean birth, the existing surgical incision may be used.

·       Conservative surgical interventions (compression sutures and/or arterial ligation) may be attempted as a second line, depending on clinical circumstances and available expertise.

·       Timing is critical. Surgical interventions should be initiated sooner rather than later.

·       Weigh benefits of conservative versus aggressive management (hysterectomy)

Strong

8.6 Hemostatic uterine suture (e.g. B-Lynch suture)

·       Judiciously apply aortic compression (below the level of the renal arteries) as a temporary measure

·       Consider B-Lynch compression or other compression suture

·       It is preferable that a laminated diagram of the brace suture technique, as B-lynch suture, be kept in theatre.

GPS

8.7. Arterial ligation: Stepwise arterial ligation for uterine devascularization may be considered depending on clinical circumstances and available expertise:

·       Bilateral uterine artery ligation

·       Bilateral utero-ovarian artery ligation

·       If expertise available, bilateral internal iliac artery ligation

GPS

8.8. Hysterectomy:

 

8.8.1. Resort to hysterectomy early (sooner rather than later) especially if:

·       Life is threatened (hemodynamic unstable patient),

·       Bleeding continues after use of conservative treatment options

·       blood transfusion is limited or not an option.

·       In cases of placenta accreta or uterine rupture.

Strong

8.8.2.   Subtotal (Supra-Vaginal) hysterectomy is quicker and safer in Major PPH and in packing of the abdomen, use hot packs.

GPS

8.8.3.   Ideally and when feasible, a second experienced clinician should be involved in the decision for hysterectomy.

GPS

8.8.4.   In rare situations in spite of compression, arterial ligation and hysterectomy, bleeding from undefined origin might persist in the pelvis (undefined diffuse venous bleeding or bleeding due to DIC). Tight pelvic packing with radio-opaque packs, done by a senior obstetrician, may be a last resort to be followed by temporarily closing the abdomen, stabilization of the patient condition by multidisciplinary team, then reopening the abdomen again to remove the packs and reassess hemostasis after 24-48 hours.

Conditional

9.         RISK MANAGEMENT

 

9.1.          Training and Preparation

 

Every maternity unit should have a multidisciplinary protocol for the management of PPH.

GPS

All staff involved in maternity care should receive training in the management of obstetric emergencies, including the management of PPH.

Strong

Training for PPH should be multidisciplinary and multiprofessional including team rehearsals.

Strong

All cases of PPH involving a blood loss of greater than 1500 ml should be the subject of a formal clinical incident review.

GPS

9.2.          Documentation

 

Accurate documentation of a delivery with PPH is essential.

GPS

9.3.          Consent

 

If treatment is likely to affect woman’s fertility, prioritize gaining informed consent.

Strong

10.      Postnatal Care

 

Upon discharge: Educate about signs, symptoms and self-referral regarding persistent or increasing bleeding, infection and risk of secondary PPH, postnatal depression, and venous thromboembolism

GPS

Oral iron supplementation, either alone or in combination with folic acid, may be provided to postpartum women for 6–12 weeks after delivery for reducing the risk of anemia.

Conditional

Offer the woman and family debriefing/clinical disclosure by senior team members, preferably by clinicians who were at the event

Offer additional opportunities for discussion/debrief six weeks postpartum

GPS

 


 

  Jump to activity

Clinical Guideline · 09

The management of nausea and vomiting during pregnancy

last update: 30 December 2025”
Download Guideline
– Executive Summary136 بندعرض التوصيات
“last update: 30 December  2025”                                                                            Download Guideline
 

– Executive Summary

 

This guideline offers evidence-based recommendations on the management of nausea and vomiting during pregnancy. The recommendations are intended to provide healthcare professionals with practical guidance on appropriate and timely diagnosis and choosing the best evidence-based treatment modality of nausea and vomiting during pregnancy resulting in improving health outcomes for people with this condition that may considerable affect fetal and maternal health.

List of Recommendations

Recommendation

Strength

Diagnosis of nausea and vomiting during pregnancy

 

NVP is diagnosed when onset is prior to 16 weeks of gestation and other causes of nausea and vomiting have been excluded.

Strong

HG is diagnosed when symptoms start in early pregnancy, nausea and/or vomiting are severe enough to cause an inability to eat and drink normally and strongly limits daily activities of living (see the differential diagnosis of NVP in appendix1).

Strong

An objective and validated index of nausea and vomiting such as the PUQE tool (see appendix 2) can be used to classify the severity of NVP and HG.

Conditional

Clinicians should be aware of the features in history, examination and investigation that allow appropriate assessment of NVP and HG and to monitor severity.

Strong

Ketonuria is not an indicator of dehydration in pregnancy and should not be used to assess severity.

Strong

Non-Pharmacological therapies of NVP and HG

 

Avoid an empty stomach at all times, with small and frequent meals every 1–2h.

Strong

Prevent a full stomach (ie. not mixing solid with liquid, avoiding large meals).

Strong

Eat dry food, high-protein snacks, and crackers in the morning before arising.

Strong

Avoid strong tasting and spicy food, eliminate supplemental iron.

Strong

Ginger, has shown a beneficial effect in reducing nausea symptoms, but not in reducing vomiting.

Strong

We recommend against acupuncture, acupressure and hypnosis.

Strong

Pharmacological therapies

 

Combinations of different drugs should be used in women who do not respond to a single antiemetic.

GPS

For women with persistent or severe HG, non-oral routes may be necessary and more effective than an oral regimen

Conditional

Stepwise approach for mild and moderate NVP without hypovolemia:

–     Doxylamine/pyridoxine (vitamin B6) is recommended as the first-line therapy for mild-moderate NVP: Doxylamine/pyridoxine 20/20mg PO at night, increase additional 10/10 mg in morning and 10/10mg at lunchtime if required.

If no adequate response, ADD antihistaminic:

–     Cyclizine 50 mg PO, IM or IV 8 hourly

–     Promethazine 12.5–25 mg 4–8 hourly PO, IM or IV.

If no adequate response, ADD dopamine antagonists:

–     Prochlorperazine 5–10 mg 6–8 hourly PO (or 3 mg buccal); 12.5 mg 8 hourly IM/IV; 25 mg PR daily.

–     Metoclopramide 5–10 mg 8 hourly PO, IV/IM/SC.

–     Domperidone 10 mg 8 hourly PO; 30 mg 12 hourly PR.

If no adequate response, ADD:

–     Ondansetron 4 mg 8 hourly or 8 mg 12 hourly PO; 8 mg over 15 minutes 12 hourly IV; 16 mg daily PR (Women taking ondansetron may require laxatives if constipation develops).

If no adequate response, ADD:

–     Hydrocortisone 100 mg twice daily IV and once clinical improvement occurs, convert to prednisolone 40–50 mg daily PO, with the dose gradually tapered (by 5-10 mg per week) until the lowest maintenance dose that controls the symptoms is reached (Corticosteroids should be reserved for cases where standard therapies have failed; when initiated they should be prescribed in addition to previously started effective antiemetics.

–     Women taking corticosteroids should have their blood pressure monitored and a screen for diabetes mellitus).

Strong

Acid-reducing agents can be used as adjunctive therapy in patients with heartburn/acid reflux and NVP.

Conditional

In women with severe NVP or HG, input could be sought from other allied professionals.

Conditional

Women with previous or current NVP or HG should consider avoiding iron-containing preparations if these exacerbate symptoms or consider alternative route of administering iron.

Conditional

Histamine type-2 receptor blockers or proton pump inhibitors may be used for women developing gastro-oesophageal reflux disease, oesophagitis or gastritis.

Conditional

Management of NVP-HG with hypovolemia

 

Hospital admission for close monitoring and ongoing treatment is appropriate for those with persistent inability to tolerate oral intake resulting in hypovolemia requiring intravenous replacement fluid, and failure of oral and/or intravenous antiemetic therapy.

Strong

The goal of inpatient management is to restore oral intake to enable adequate hydration and nutrition and use of oral antiemetic therapy after discharge.

Strong

The decision to discharge needs to be individualized based on the patient’s ability to access outpatient resources.

Strong

A baseline electrocardiogram is indicated in patients with electrolyte abnormalities requiring replacement.

Strong

Fluid replacement:

–   Aggressively rehydrate with up to 2 liters of IV crystalloid over two hours (preferably with lactated Ringer’s due to decreased incidence of acute kidney injury compared with normal or isotonic saline).

–   After initial resuscitation, titrate IV fluids to maintain urine output at least 100 mL/hour or continue at a rate of 125 to 150 mL/hour, with close monitoring of oral intake and urine output.

–   Then switch to dextrose-saline (dextrose 5% in 0.45% saline) at a rate of 150 mL/hour. For patients with normal potassium levels, add 10 mEq potassium chloride for each 500 ml.

Strong

Urea and serum electrolyte levels should be checked daily in women requiring intravenous fluids.

In patients with electrolyte imbalance, consult intensive care specialist to correct the imbalance.

GPS

Thiamine:

–   To reduce the risk of Wernicke encephalopathy, 100 to 200 mg thiamine (vitamin B1) should be added to the initial fluid resuscitation and then daily thereafter while the patient is taking nothing-by-mouth or for two to three days in patients with oral intake.

–   If Wernicke encephalopathy is suspected, treat with 200 to 500 mg IV every eight hours for 2 to 7 days, followed by 250 mg once daily for an additional 3 to 5 days, followed by maintenance therapy 100 mg daily until no longer at risk for deficiency. Thiamine should be administered before administering glucose.

Strong

Other vitamins:

–   A multivitamin may be given intravenously each day (folic acid and pyridoxine).

–   Vitamin K addition is not necessary unless to treat a coagulopathy (add 150 mcg vitamin K).

Conditional

Antiemetics:

–   Begin with ondansetron 4 mg intravenously (IV push) once every eight hours upon hospitalization for intravenous fluid therapy and may increase to 8 mg IV every eight hours. After the patient has stabilized, ondansetron is discontinued. OR

–   Intravenous dimenhydrinate 50 mg every four to six hours, metoclopramide 5 to 10 mg every eight hours, or promethazine 12.5 to 25 mg every four to six hours is an alternative to ondansetron.

–   Parenteral medications can be discontinued and oral medications started after 24 to 48 hours of gastrointestinal rest and when the patient is tolerating oral intake.

Strong

Thromboprophylaxis:

–   Women admitted with HG should be offered thromboprophylaxis with low-molecular-weight heparin and those being managed as outpatients should be assessed for VTE risk.

–   Graduated compression stockings should be used when low-molecular-weight heparin is contra-indicated.

–   Thromboprophylaxis can be discontinued upon discharge providing no other indications exist for continuation of thromboprophylaxis.

Strong

Management of patients with refractory NVP and HG

 

Consider testing for H. pylori infection in patients unresponsive to standard therapy, who have symptoms beyond the first trimester, who require multiple hospitalizations, or who have symptoms of gastroesophageal reflux disease.

Conditional

Enteral or parenteral nutrition

 

When all other medical therapies have failed to sufficiently manage symptoms, enteral tube feeding or parenteral nutrition should be considered with a referral to a specialized physician in clinical enteral and parenteral nutrition in parallel to ongoing medical therapies.

Strong

Hospitalization

 

Inpatient care should be considered if there is at least one of the following:

–     Continued nausea and vomiting and inability to keep down oral antiemetics.

–     Continued nausea and vomiting associated with clinical dehydration or weight loss (greater than 5% of body weight), despite oral antiemetics.

–     Confirmed or suspected comorbidity (such as urinary tract infection and inability to tolerate oral antibiotics).

–     Comorbidities such as epilepsy, diabetes, HIV, hypoadrenalism or psychiatric disease where symptoms and inability to tolerate oral intake and medication could present further complications.

GPS

Antenatal care after hospital discharge

 

Women should only be discharged once:

–     Appropriate antiemetic therapy has been tolerated.

–     Adequate oral nutrition and hydration have been tolerated.

–     Management of concurrent conditions is completed.

GPS

At the time of discharge, it is essential that women are advised to continue with their antiemetics for at least one week and that they know how to access further care.

Strong

Women with severe NVP or HG who have continued symptoms into the late second or the third trimester should be offered serial scans to monitor fetal growth.

Strong

Long-term effects of NVP and HG on women

 

There is no evidence of significant impact on long-term all-cause mortality.

Strong

Women who experience HG in pregnancy are at increased risk of PND, anxiety, and PTSD

Strong

Women with previous HG should be advised that there is a risk of recurrence in future pregnancies.

Strong

Future pregnancies

 

Early use of lifestyle/ dietary modifications and antiemetics that were useful in the index pregnancy is advisable to reduce the risk of NVP and HG in the current pregnancy

Strong


 

  Jump to activity

Clinical Guideline · 10

Normal Labor

last update: 30 April 2026”
Download Guideline
– Executive Summary589 بندعرض التوصيات
“last update: 30 April  2026”                                                                              Download Guideline
 

– Executive Summary

 

This guideline offers evidence-based recommendations on diagnosis and management of normal labor and delivery. The recommendations are intended to provide healthcare professionals with practical guidance on appropriate care and management of women in normal labor. With the aim that proper management of labor would decrease number of unindicated cesarean sections.

List of Recommendations

Recommendation

Strength

History taking:

 

·   Review history, pregnancy notes and screening results including:

–             Gestational age

–             Past history (medical, obstetric, gynecological, surgical, social, family)

–             Medications, allergies

–             Pregnancy complications

–             Investigation results (including placental location)

·              Ask her about the length, strength and frequency of her contractions

·              Ask about fetal movements in the last 24 hours

·              Ask for vaginal losses

·              Review if there are any antenatal or intrapartum risk factors for fetal hypoxia (see the NICE guideline on fetal monitoring in labor)

·              Review ER visit history and clinical circumstances at each visit

·              Assess emotional and psychological needs

 

Strong

Geneal examination:

 

·              Temperature, pulse, respiratory rate, blood pressure (BP), and urinalysis

·              Assess nutrition and hydration status and general appearance

Strong

Abdominal examination

 

·              Observation, and palpation including:

–              fundal height, fetal lie, attitude, presentation, position, engagement/descent

·              Record time of maternal account of regular, painful contractions:

Assess strength, frequency, duration and resting tone for 10 minutes

Strong

Auscultation of FHS

 

·              Intermittent auscultation using either a Pinard stethoscope or a handheld Doppler ultrasound device (e.g. Doptone® or SonicAid®).

·              Auscultate the fetal heart rate for a minimum of 1 minute immediately after a contraction; palpate the woman’s pulse to differentiate between the heartbeats of the woman and the baby.

·              Differentiate between maternal and fetal heartbeat.

 

Strong

Vaginal examination

 

Indication of VE

·              If there is uncertainty about whether the woman is in established labor, a vaginal examination may be helpful after a period of assessment, but is not always necessary

·              If the woman appears to be in established labor, offer a vaginal examination.

·              If spontaneous rupture of membranes (SROM) suspected, consider a dry sterile speculum examination.

·              Routine clinical pelvimetry on admission in labor is not recommended for healthy pregnant women.

·              Assess and record vaginal loss

–        Discharge—note color, odor, consistency

–        Blood—note color, volume

–        Liquor—note color, volume, odor, consistency

–        Presence of meconium

·              Document the presence or absence of meconium.

–        If meconium is present, consider the character of the meconium.

–        Meconium may increase the risk to the baby means that:

–        Continuous CTG monitoring may be advised

–        Healthcare professionals trained in advanced neonatal life support are needed as soon as the baby is born.

Contraindication to VE

·              Antepartum hemorrhage

·              Ruptured membranes and not in labor

·              Placenta previa

·              Placental position unknown

·              Suspected preterm labor

Prior to VE

·              Review history and most recent ultrasound scan result

·              Explain procedure and gain verbal consent prior to each examination

·              Ensure the woman’s privacy, dignity and comfort

·              Ensure bladder is empty

·              Perform abdominal examination and FHR auscultation

·              Tap water may be used if cleansing is required before vaginal examination.

During VE

·              Maintain privacy, dignity and respect

·              Keep the woman informed of findings during the examination

·              Perform VE between contractions

·              Assessment:

–        Observe general appearance of perineal and vulval area

–        Position of cervix—posterior, mid, anterior

–        Dilatation

–        Effacement

–        Consistency—soft, medium, firm

–        Application of presenting part

–        Membranes intact/no membranes felt

–        Liquor—note color, volume, odor

–        Fetal station: level of presenting part in relation to ischial spines (- 3 to + 3)

–        Presence of caput and molding

–        Fetal position and attitude

After VE

·              Discuss any potential impact on the birth plan

·              Auscultate FHR

·              Document findings

 

 

 

 

 

 

Strong

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Strong

Laboratory investigation:

 

·              Hb concentration (if not performed in the past month)

·              Blood group and Rh typing (if not performed before)

–       In Rh negative mothers with Rh positive husband, request indirect Coomb’s test if available

 

GPS

Admission

 

Criteria for admission to labor ward

·              Admission decisions should take into account:

–        Maternal and fetal wellbeing

–        Labor progress (e.g., dilation, contractions)

–        Complicating risk factor indicating hospital admission.

·              Criteria of admission to labor ward in low-risk women:

–        Active stage of labor

–        ROM

·              Women with cervical dilatation < 5cm and good uterine contractions should be observed for 2 hours and admit to labor ward if the cervix dilates 1 cm or more.

 

 

Conditional

General Care and support for normal labor

 

·              Providers, senior staff and all healthcare professionals should ensure that in all birth settings there is a culture of respect for each woman as an individual undergoing a significant and emotionally intense life experience, so that the woman is in control, is listened to and is cared for with compassion, and that appropriate informed consent is sought.

 

GPS

·              Maintain the minimum level of birth intervention compatible with safety.

Strong

Eating and drinking

 

·              Explain to the woman or pregnant person that they should drink during labor when they are thirsty, and that isotonic drinks may be more beneficial than water. Also explain that there is no benefit to drinking any more than normal, and overconsumption may be harmful.

 

Strong

·              Inform the woman or pregnant person that they can eat a light diet in established labor if they wish, unless they have received opioids or they develop risk factors that make a caesarean birth more likely.

 

Conditional

Fluid intake and output:

 

·              Discuss with the woman or pregnant person that:

–       it is important to drink during labor when thirsty

–       it is important to regularly empty the bladder

–       excessive intake of oral or intravenous fluids may be harmful as this can cause hyponatremia (a sodium level of less than 130 mmol/L in a pregnant woman or pregnant person) and lead to maternal and neonatal seizures or death

–       their midwife will ask about and check up on their fluid intake and output throughout labor

–       fluid balance monitoring may be advised during labor to reduce the risk of hyponatremia or dehydration

 

 

 

 

Strong

·              Monitor and record fluid balance, if:

–       there are any concerns about fluid intake, for example the woman or pregnant person is drinking too much (also take into account fluid intake before labor care began)

–       the woman or pregnant person is receiving intravenous fluids

–       the woman or pregnant person is receiving an oxytocin infusion

–       there are any concerns about fluid output, for example there is an inability to pass urine, nausea, vomiting or diarrhea there are certain medical conditions, such as hemorrhage or pre-eclampsia

 

 

 

Strong

·              If there is a positive fluid balance of 1500 ml or more, or there are clinical concerns (for example, signs and symptoms of hyponatremia):

–       explain to the woman or pregnant person that it is possible they are developing, or have developed, hyponatremia

–       request an obstetric review

–       offer a blood test to check their sodium level

–       advise that they will need to be transferred to an obstetric setting if they are currently in a midwifery-led setting

 

Conditional

·              Do not routinely advise oral fluids or give intravenous fluids for the treatment of ketonuria in pregnant women who are not diabetic.

Strong

Pain management

 

·              When women are observed or admitted for pain or fatigue in latent labor, techniques such as education and support, oral hydration, positions of comfort, and nonpharmacologic pain management techniques (such as breathing exercises, having a shower or bath, massage or application of warm packs) may be beneficial.

 

Conditional

Hygiene

 

·              Routine hygiene measures taken by staff caring for women in labor, including standard hand hygiene and single-use non-sterile gloves, are appropriate to reduce cross-contamination between women, babies and healthcare professionals.

 

GPS

Perineal/pubic shaving

 

·              We recommend against routine perineal/pubic shaving prior to giving vaginal birth.

Conditional

Enema on admission

 

·              We recommend against administration of an enema for reducing the use of labor augmentation.

Strong

Return/remain at home

 

·   – If there is no indication for immediate admission, and the woman returns or remains at home, provide information on:

–       When to return/make contact, including if:

–  Increased frequency, strength and duration of contractions

–  Increased pain or discomfort requiring additional support

–  Vaginal bleeding and//or membrane rupture

–  Reduced or concern about fetal movements

–       Plan an agreed time for reassessment at each contact

Strong

First stage of labor

 

Latent phase:

 

·    – Duration of the latent stage: Women should be informed that a standard duration of the latent first stage has not been established

GPS

·  Assessment in latent phase:

–       Review birth plan and provide individualized support including:

–  Encourage ongoing resilience and positive self-belief

– Rest, hydration, nutrition, mobilization, support

– Reassurance

 

 

Strong

·              Slow progress in latent stage:

–       Limited high-quality evidence to provide a contemporary definition

–       Historically, limits of more than 20 hours (nulliparous women) and more than 14 hours (multiparous women) were applied to identify prolonged latent phase

–       Limits not recommended as an indication for intervention when maternal and fetal condition are reassuring

–       Labor may not naturally accelerate until a cervical dilatation threshold of 5 cm is reached. Therefore, the use of medical interventions to accelerate labor and birth (such as oxytocin augmentation or caesarean section) before this threshold is not recommended, provided fetal and maternal conditions are reassuring

Strong

·              If slow progress is suspected, assess to identify:

–       Developing complications

–       Reassuring maternal and fetal condition

–       Emotional and physical needs

Strong

Active phase of 1st stage

 

·              Duration of the active first stage: The duration of active first stage (from 5 cm until full cervical dilatation) usually does not extend beyond 12 hours in first labors, and usually does not extend beyond 10 hours in subsequent labors.

GPS

 

·              Progress of the first stage of labor: In active labor, cervical dilatation of 0.5 cm per hour (2 cm in 4 hours) is considered normal

Strong

·              Consider all aspects of labor progress including:

–       Maternal behavior

–       Fetal condition

–       Cervical dilatation and rate of change

–       Descent and rotation of the fetal head

–       Strength, duration and frequency of contractions

–       Parity

–       Previous labor history

–       Slowing of progress in the multiparous woman

Strong

·              We recommend against the use of active management of labor for prevention of delay in labor.

Conditional

·              Do not routinely use amniotomy and or oxytocin to prevent delayed progress in 1st stage of labor.

Conditional

·              We recommend against the use of intravenous fluids with the aim of shortening the duration of labor.

Strong

·              We recommend against the use of oxytocin for prevention of delay in labor in women receiving epidural analgesia.

Strong

·              We recommend against routine vaginal cleansing with chlorhexidine during labor for the purpose of preventing infectious morbidities.

Strong

Ongoing care during active phase of first stage:

 

·              Digital vaginal examination (VE)

–       Minimize VE: VE at intervals of two hours is recommended for routine assessment of active first stage of labor in low-risk women.

–       Offer additional VE if:

–  At time of ROM

– Suspected second stage

GPS

·              Advice the woman to pass urine regularly to avoid full bladder.

GPS

·              Maternal mobility and position:

–       There is little evidence that any one position is optimal in labor

–       Avoid supine position as it is associated with adverse effects including

–  Supine hypotension

– Abnormal FHR

Strong

Fetal heart assessment:

 

·              We recommend against the use of continuous cardiotocography for assessment of fetal well-being in normal labor

Strong

·              Intermittent fetal heart rate monitoring: Intermittent auscultation of the fetal heart rate with either a Doppler ultrasound device (e.g. Doptone® or SonicAid®) or a Pinard fetal stethoscope is recommended for normal labor.

·              Interval: Auscultate every 15–30 minutes in active first stage of labor, and every 5 minutes in the second stage of labor.

·              Duration: Each auscultation should last for at least 1 minute; if the FHR is not always in the normal range (i.e. 110–160 bpm), auscultation should be prolonged to cover at least three uterine contractions.

·              Timing: Auscultate during a uterine contraction and continue for at least 30 seconds after the contraction.

·              Recording: Record the baseline FHR (as a single counted number in beats per minute) and the presence or absence of accelerations and decelerations.

Strong

Partogram

 

·              Start using partogram when active labor is confirmed for documentation and providing a visual overview of progress.

·              Record the following observations during the first stage of labor in the partogram:

–       half-hourly documentation of frequency of contractions

–       hourly pulse

–       4-hourly temperature, blood pressure and respiratory rate as a minimum; in addition to other observations according to situation

Strong

 

Strong

Maternal and fetal warning signs

 

·              If any of the warning signs are present or developed during labor, consult a specialist care:

–       pulse over 120 beats/minute on 2 occasions 15 to 30 minutes apart

–       a single reading of either raised diastolic blood pressure of 110 mmHg or more or raised systolic blood pressure of 160 mmHg or more

–       either raised diastolic blood pressure of 90 mmHg or more or raised systolic blood pressure of 140 mmHg or more on 2 consecutive readings taken 15 to 30 minutes apart

–       a reading of 2+ of protein on urinalysis and a single reading of either

–       raised diastolic blood pressure (90 mmHg or more) or raised systolic blood pressure (140 mmHg or more)

–       respiratory rate of less than 9 or more than 21 breaths per minute on 2 occasions 15 to 30 minutes apart

–       temperature of 38°C or above on a single reading, or 37.5°C or above on 2 consecutive occasions 1 hour apart; for advice on intrapartum antibiotics

–       fresh red bleeding or blood-stained liquor

–       the new appearance of meconium

–       pain reported by the woman that differs from the pain normally associated with contractions

–       confirmed delay in the first stage of labor

–       obstetric emergency, including antepartum hemorrhage, cord prolapse, maternal seizure or collapse, or a need for advanced neonatal resuscitation

–       any non-cephalic presentation, including cord presentation

–       high (4/5 to 5/5 palpable) or free-floating head in a nulliparous woman

–       suspected fetal growth restriction or macrosomia

–       suspected anhydramnios or polyhydramnios

–       any alarming fetal heart rate pattern

Strong

 Delayed progress in active first stage (protracted labor)

 

·              If delayed progress in the established first stage is suspected, assess:

–       cervical dilatation of less than 2 cm in 4 hours

–       descent and rotation of the baby’s head 

–       strength, duration and frequency of uterine contraction

–       condition of fetal membranes

Strong

·              Offer the woman support, hydration, and appropriate and effective pain relief.

Strong

Management of delayed/protracted first stage or arrest of labor

 

·              Discuss the findings and the options available with the woman, and support her decision.

Strong

·              For women with intact membranes in whom delay in the established first stage of labor is confirmed:

–       consider amniotomy if membranes are intact

–       oxytocin if inertia was diagnosed and

–       repeat vaginal examination 2 hours later.

GPS

·              If available, offer the woman an epidural analgesia before oxytocin is started or if she requests it later.

Conditional

·              If oxytocin is used in the first stage of labor, ensure that the time between increments of the dose is no more frequent than every 30 minutes. Increase oxytocin until there are 3 to 4 contractions in 10 minutes.

Strong

·              Oxytocin must be discontinued immediately if there is abnormality in fetal heart rate is observed.

Strong

·              Consider restarting oxytocin in the first stage of labor if:

–       Obstetric review has been carried out and the FHR is no longer abnormal.

–       Base the dose when restarting on a full clinical assessment, taking into consideration the previous dose.

Conditional

·              Perform vaginal examination 2 hourly after the oxytocin infusion has led to regular contractions:

–       If cervical dilatation has increased by less than 2 cm after 4 hours of oxytocin, or there is arrest of labor, further obstetric review is needed by a senior obstetrician to assess whether a caesarean birth is advisable.

Strong

Second stage of labor

 

·              Assessment of women during the second stage of labor

–       Continue with observations of the woman and baby, and assessment of risk as described for the first stage of labor and, but be aware that the frequency of fetal monitoring should increase.

–       Increase Frequency of observations if clinically indicated.

Strong

·              Vaginal examination.

–       To assess progress, the vaginal examination should include:

§  position of the head

§  descent

§  caput and molding

GPS

·              Fundal pressure

–       Application of manual fundal pressure to facilitate childbirth during the second stage of labor is not recommended.

Strong

·              Techniques for preventing perineal trauma

–       For women in the second stage of labor, techniques to reduce perineal trauma and facilitate spontaneous birth (including perineal massage, warm compresses and a “hands on” guarding of the perineum) are recommended

Strong

Episiotomy policy

 

·              Routine or liberal use of episiotomy is not recommended for women undergoing spontaneous vaginal birth.

Strong

·              If an episiotomy is performed, the recommended technique is a mediolateral episiotomy originating at the vaginal fourchette and usually directed to the right side. The angle to the vertical axis should be between 45 and 60 degrees at the time of the episiotomy.

Strong

·              Perform an episiotomy if there is a clinical need, such as birth with forceps or ventouse or suspected fetal compromise.

·              Provide tested, effective analgesia before carrying out an episiotomy, except in an emergency because of acute fetal compromise.

Strong

Shortening of the 2nd stage

 

·              Delay in active second stage is diagnosed when:

–       In nulliparous woman (any of): either insufficient flexion/rotation/descent within 1 hour or the second stage duration is > 2 hours.

–       In multiparous woman (any of): either insufficient flexion/rotation/descent within 30 minutes or the second stage duration is > 1 hour.

–       Longer durations may be appropriate where maternal and fetal conditions are optimal.

GPS

·              A specific absolute maximum length of second stage (passive plus active) has not been identified. Rather than rigid time limits, base decision-making on continuing assessment of:

–       Maternal physical and emotional condition

–       Fetal condition

–       Progress of labor

–       Maternal preferences

Strong

·              Operative vaginal delivery in second stage of labor by experienced and well-trained physicians should be considered safe, acceptable alternative to cesarean delivery.

·              Training in, and ongoing maintenance of, practical skills related to operative vaginal delivery should be encouraged.

Strong

Third stage of labour

 

Management of third stage of labor

 

·              The use of uterotonics for prevention of PPH during the third stage of labor is recommended for all births.

Strong

·   Cord clamping:

–       Late cord clamping (performed approximately 1 to 3 minutes after birth) is recommended for all births while initiating simultaneous essential newborn care.

–       Early cord clamping (<1 minute after birth) is not recommended unless the neonate is asphyxiated and needs to be moved immediately for resuscitation.

     

 

Strong

 

Strong

·   Controlled cord traction:

–       Consider Controlled cord traction (CCT) as part of active/modified active management of third stage as it may.

–       Providers employing CCT should only do so after signs of placental separation, and traction should be performed with uterine contraction as these measures reduce the risk of uterine inversion, cord avulsion, and partial detachment of the placenta.

 

Strong

 

 

Strong

Prophylactic Uterotonics:

 

·    Oxytocin:

–       In most circumstances, oxytocin is the prophylactic uterotonic of choice.

–       For vaginal birth

– If vaginal birth with IV access: Oxytocin 10 IU IV injected slowly over 3–5 minutes is recommended in preference to IM

–  If vaginal birth without IV access: Oxytocin 10 IU IM

–       For CS birth:

–  Oxytocin 5 IU IV over 1–2 minutes

§  Monitor for hemodynamic impact

§  Avoid rapid IV bolus administration

–       If cardiovascular compromise exists (e.g. hypovolemia, shock, cardiac disease), use caution with IV administration.

Strong

·    Ergometrine:

–       Ergometrine can be given IM or, in life-saving circumstances, as a slow IV injection.

–       Ergometrine should not be used in patients with essential or gestational hypertension, or in patients on HIV protease inhibitors.

–       Though undisputedly extremely effective, potential adverse effects limit ergometrine to a second-line agent.

Conditional

 

 

Strong

 

Conditional

·  Carbetocin:

–       Routinely use oxytocin in preference to carbetocin if vaginal birth and cold-chain storage of oxytocin can be guaranteed (e.g. hospital setting).

–       If vaginal birth and cold-chain storage of uterotonics cannot be guaranteed:

–  Carbetocin is an effective alternative uterotonic

–  IM is preferred route of administration

–       If CS birth under regional anesthetic: IV carbetocin may be considered as a cost-effective uterotonic.

–       If CS birth under general anesthetic: Carbetocin is not recommended due to insufficient evidence.

–       If used: used as a single dose only, not for repeated use

Conditional

·              Misoprostol:

–       Not recommended if alternative injectable uterotonics are available

–       Use only if no other injectable uterotonic is available (e.g. due to unexpected birth in low resource setting or if storage conditions for uterotonics are inadequate).

–       The dose is 600 micrograms orally or sublingual single dose immediately after birth

–       If in a low resource setting with limited PPH treatment capability, consider use if:

–  an injectable uterotonic has been administered and

–  continued bleeding is anticipated and/or blood loss is estimated to be greater than or equal to 350 mL  

Conditional

Tranexamic Acid (TXA) For Prophylaxis in High-Risk Women

 

·              Tranexamic acid can be used as a prophylactic agent as an adjunct to uterotonics in patients at high risk for postpartum hemorrhage.

·              Use TXA within 3 hours of birth of the baby in a fixed dose of 1 g in 10 mL IV over 10 minutes (100 mg/min i.e. 1 ml /minute)

Strong

Prolonged third stage

 

·              Diagnose a prolonged third stage of labor if it is not completed within 30 minutes of the birth with active management or within 60 minutes of the birth with physiological management

Strong

Placenta and membranes examination

 

·              Perform a thorough examination of the placenta and membranes:

–       Placenta:

–  General shape and appearance

–  Calcification or infarctions

–  Evidence of abruption

–  Missing cotyledons

–  Succenturiate lobe/s

–       Membranes:

–  One amnion and one chorion

–  Complete or ragged

– Presence of vessels

–       Cord:

–  Cord insertion site

–  Two arteries and one vein

– Velamentous insertion: Vessels noted in membranes

 

 

 

 

 

Strong

Immediate Postpartum Risk Management

 

·   Uterine massage:

–       Sustained uterine massage is not recommended as an intervention to prevent PPH in women who have received prophylactic oxytocin.

Strong

·              Uterine tonus assessment:

–       Postpartum abdominal uterine tonus assessment for early identification of uterine atony is recommended for all women.

Strong

·              Nipple stimulation & breast feeding:

–       Nipple stimulation and/or early breastfeeding may increase uterine activity but has not been shown to reduce bleeding or incidence of PPH.

Strong

·              Observation for women in the first 2 hours postpartum:

–       Vital signs: Respiratory rate, pulse rate, and blood pressure, every 15-30 minutes in the first hour and every 30 minutes in the second hour.

–       Blood Loss every 15-30 minutes by visualizing the labia and perineum and be alert for slow steady trickle.

–       Uterine tonus assessment

–       Temperature every 30 minutes

–       Urine output: after the first 2 hours

·              After the first 2 hours continue as clinically indicated

 

 

 

 

Strong

·              Women who have had regional analgesia or anesthesia:

–       Check that women who have had regional analgesia or anesthesia can perform a straight leg raise by 4 hours after the last anesthetic dose. If not, contact the obstetric anesthetist for urgent review.

Strong

·              Antibiotics use with normal labor:

 

–       Use according to the local protocols

GPS

Episiotomy/1st and 2nd degree perineal tears repair

 

·              Ensure that tested effective analgesia is in place, using infiltration with up to 20 ml of 1% lidocaine or equivalent

 

 

 

 

 

 

 

 

 

 

Strong

·              Top up the epidural or insert a spinal anesthetic if necessary

·              If the woman reports inadequate pain relief at any point, manage immediately with pharmacological and/or non-pharmacological measures

·              In episiotomy and first/second degrees tears, the wound should be sutured in order to improve healing.

·              Suture use a continuous subcuticular technique

·                    Undertake perineal repair using a continuous non-locked suturing technique for the vaginal wall and muscle layer.

·              Use an absorbable synthetic suture material to suture the perineum.

·              Offer rectal non-steroidal anti-inflammatory drugs routinely after perineal repair of first- and second-degree trauma provided these drugs are not contraindicated.

·              Ensure that suture material has not been accidentally inserted through the rectal mucosa by carrying out a rectal examination after completing the repair

·              After completion of the repair, document an accurate detailed account covering the extent of the trauma, the method of repair and the materials used

·              Give the woman information about the extent of the trauma, pain relief, diet, hygiene and the importance of learning to do pelvic floor exercises, what to expect as they recover, and where and when to seek advice or psychological support if needed.

Postnatal discharge following uncomplicated vaginal birth

 

·              After an uncomplicated vaginal birth in a health care facility, we advise that healthy mothers and newborns receive care in the facility for 12 – 24 hours after birth.

GPS

·              Physiological care

–       Respond to requests for pain management

–       Consider personal hygiene needs

–       Observe emotional and psychological response to labor and birth

–       Observe response towards the baby and encourage breast feeding

–       Venous thromboembolism (VTE) risk re-assessment

–       Iron supplementation is advised.

GPS

·              Rh D negative blood group

–       Test the baby’s Rh status

–       We recommend Rh D immunoglobulin if maternal indirect Coomb’s test is negative

Strong

Intrapartum analgesia

 

·              Non-pharmacological pain-relieving strategies

–       Advise women that breathing exercises, and having a shower or bath, may reduce pain during the latent first stage of labor.

Conditional

·              Pharmacological analgesia

 

–       Opioid analgesia for pain relief

–  Parenteral opioids, such as fentanyl, diamorphine and pethidine, are options for healthy pregnant women requesting pain relief during labor, depending on a woman’s preferences and availability.

–  Inform the woman that these drugs will provide limited pain relief during labor and may have side effects for both her (for example, drowsiness, nausea and vomiting) and her baby (for example, short-term respiratory depression and drowsiness, which may last several days and may make it more difficult to breastfeed).

Conditional

–  It is not advisable to give opioids if delivery is expected with 3 hours

GPS

–  If an intravenous or intramuscular opioid is used, also administer an antiemetic.

Conditional

–       Antispasmodic agents

–  The use of antispasmodic agents for prevention of delay in labor is not recommended.

Conditional

·              Epidural analgesia for pain relief

 

–       Epidural analgesia may be offered for healthy pregnant women requesting pain relief during labor, depending on a woman’s preferences and availability.

Conditional

–       Obstetric care and observations for women with epidural analgesia

–  Care and observations for women with epidural analgesia should be jointly managed with the anesthetist.

– Insert urinary catheter.

–  Perform continuous cardiotocography for at least 30 minutes during establishment of epidural analgesia and after administration of each further bolus of 10 ml or more.

– On confirmation of full cervical dilatation in a woman with epidural analgesia, unless the woman has an urge to push or the baby’s head is visible, pushing may be delayed by 1 hour for multiparous women and up to 2 hours for nulliparous women, after which actively encourage her to push during contractions.

–  Do not routinely use oxytocin in the second stage of labor for women with epidural analgesia.

–  Continue epidural analgesia until after completion of the third stage of labor and any necessary perineal repair.

Strong